

Approved



Mozambique
Country Operational Plan
FY 2016



Budget Summary Reports

Summary of Planned Funding by Agency and Funding Source

Agency	Funding Source			Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
	GAP	GHP-State	GHP-USAID			
State		1,677,807		1,677,807	323,780	2,001,587
USAID		125,285,950		125,285,950	19,449,089	144,735,039
DOD		4,487,251		4,487,251	0	4,487,251
PC		3,098,458		3,098,458	0	3,098,458
HHS/CDC	3,075,000	166,976,238		170,051,238	6,900,000	176,951,238
HHS/HRSA		3,758,333		3,758,333	0	3,758,333
State/AF		2,044,003		2,044,003	0	2,044,003
Total	3,075,000	307,328,040	0	310,403,040	26,672,869	337,075,909

Summary of Planned Funding by Budget Code and Agency

Budget Code	Agency							On Hold Amount	Total
	State	DOD	HHS/CDC	HHS/HRSA	PC	State/AF	USAID		
CIRC		2,081,768	18,222,295	966,468			6,022,955	0	27,293,486
HBHC	152,322	65,393	12,516,302			235,059	14,483,766	0	27,452,842
HKID	103,934			340,340	156,652	411,227	6,298,368	0	7,310,521
HLAB		7,030	4,793,840			1,184,003	841,227	0	6,826,100
HMBL			698,379					0	698,379
HTXD			48,737				31,795,281	0	31,844,018
HTXS	35,141	1,695,392	69,313,206	1,630,806			34,118,268	0	106,792,813
HVAB	15,218						9,155	0	24,373
HVCT	27,082	267,459	9,838,751			26,794	5,208,866	0	15,368,952

Approved



HVMS	1,033,866	215,848	12,991,398		2,897,154		4,625,441	0	21,763,707
HVOP	116,869		2,445,387		44,652	156,920	2,328,281	0	5,092,109
HVSI	76,091		5,358,977				1,790,623	0	7,225,691
HVTB	27,531	4,921	4,975,984	385,719			2,690,303	0	8,084,458
MTCT	3,804	8,941	12,125,284	15,000			2,581,985	0	14,735,014
OHSS	15,667	2,109	4,854,015	360,000		30,000	9,374,548	0	14,636,339
PDCS	35,141	22,002	2,639,853	50,000			336,135	0	3,083,131
PDTX	35,141	116,388	9,228,830	10,000			2,780,748	0	12,171,107
	1,677,807	4,487,251	170,051,238	3,758,333	3,098,458	2,044,003	125,285,950	0	310,403,040



Technical Areas

Technical Area Summary

Technical Area: Care

Budget Code	Budget Code Planned Amount	On Hold Amount
HBHC	26,649,380	0
HKID	7,009,738	0
HVTB	7,925,660	0
PDCS	2,892,304	0
Total Technical Area Planned Funding:	44,477,082	0

Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount	On Hold Amount
HLAB	6,534,003	0
HVSI	5,211,000	0
OHSS	13,812,239	0
Total Technical Area Planned Funding:	25,557,242	0

Technical Area: Prevention

Budget Code	Budget Code Planned Amount	On Hold Amount
CIRC	26,897,492	0
HMBL	690,000	0
HVCT	15,067,262	0
HVOP	4,726,228	0
MTCT	14,288,655	0
Total Technical Area Planned Funding:	61,669,637	0

Approved



Technical Area: Treatment

Budget Code	Budget Code Planned Amount	On Hold Amount
HTXD	31,500,000	0
HTXS	105,526,162	0
PDTX	11,920,094	0
Total Technical Area Planned Funding:	148,946,256	0



Technical Area Summary Indicators and Targets

Indicator Number	Label	2017
PMTCT_STAT_DSD	PMTCT_STAT_DSD Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (DSD)	n/a
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	867,010
	Number of new ANC and L&D clients	875,737
	By: Known positives at entry	35,012
	By: Number of new positives identified	52,659
	Sum of Positives Status disaggregates	87,671
	Required only for DREAMS Countries - By Number of new positives: <15	22
	Required only for DREAMS Countries - By Number of new positives: 15-19	1,163
	Required only for DREAMS Countries - By Number of new positives: 20-24	2,572
	Required only for DREAMS Countries - By Number of known positives: <15	
	Required only for DREAMS Countries - By Number of known	522



	positives: 15-19	
	Required only for DREAMS Countries - By Number of known positives: 20-24	1,562
	Required only for DREAMS Countries - Denominator: <15	1,754
	Required only for DREAMS Countries - Denominator: <15-19	15,147
	Required only for DREAMS Countries - Denominator: 20-24	20,540
	Required only for DREAMS Countries - Denominator: 25-49	27,499
	Required only for DREAMS Countries - Denominator: 50+	61
	Required only for DREAMS Countries - By Number of known positives: 25-49	3,083
	Required only for DREAMS Countries - By Number of known positives: 50+	51
	Required only for DREAMS Countries - By Number of new positives: 25-49	3,992
	Required only for DREAMS Countries - By Number of new positives: 50+	74
	By Age (DREAMS SNU's ONLY): <15	1,735
	By Age (DREAMS SNU's ONLY): 15-19	14,996
	By Age (DREAMS SNU's ONLY): 20-24	20,336
	By Age (DREAMS SNU's ONLY): 25-49	27,221



	By Age (DREAMS SNU's ONLY): 50+	59
PMTCT_STAT_TA	PMTCT_STAT_TA Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (TA)	n/a
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	286,676
	Number of new ANC and L&D clients	289,574
	By: Known positives at entry	4,622
	By: Number of new positives identified	6,932
	Sum of Positives Status disaggregates	11,554
	Required only for DREAMS countries - By known positives: <15	
	Required only for DREAMS countries - By known positives: 15-19	
	Required only for DREAMS countries - By known positives: 20-24	
	Required only for DREAMS countries - By new positives: <15	
	Required only for DREAMS countries - By new positives: 15-19	
	Required only for DREAMS countries - By new positives: 20-24	
	Required only for DREAMS countries - Denominator: <15	



	Required only for DREAMS countries - Denominator: 15-19	
	Required only for DREAMS countries - Denominator: 20-24	
	Required only for DREAMS countries - Denominator: 25-49	
	Required only for DREAMS countries - Denominator: 50+	
	Required only for DREAMS countries - By known positives: 25-49	
	Required only for DREAMS countries - By known positives: 50+	
	Required only for DREAMS countries - By new positives: 25-49	
	Required only for DREAMS countries - By new positives: 50+	
	By Age (DREAMS SNU ^s ONLY): <15	
	By Age (DREAMS SNU ^s ONLY): 15-19	
	By Age (DREAMS SNU ^s ONLY): 20-24	
	By Age (DREAMS SNU ^s ONLY): 25-49	
	By Age (DREAMS SNU ^s ONLY): 50+	
PMTCT_ART_DSD	PMTCT_ART_DSD Percentage of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	n/a
	Number of HIV-positive pregnant women who	



	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	867,010
	New on ART	52,112
	Already on ART at beginning of current pregnancy	34,655
PMTCT_ART_TA	PMTCT_ART_TA Percentage of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	n/a
	Number of HIV-positive pregnant women who	
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	286,676
	New on ART	6,862
	Already on ART at beginning of current pregnancy	4,579
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	427,536
	By Age: 0-60 days	
	By Age: 2 months - 9 years	
	By Age: 10-14	112,458
	By Age: 15-19	114,269
	By Age: 20-24	95,221
	By Age: 25-29	57,139
	By Age: 30-49	19,043
By Age: 50+		



	Sum of age disaggregates (Prior to FY15)	321,948
	Sum of age disaggregates (FY15-Current)	398,130
	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	
	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	
	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	
	By circumcision technique: Surgical VMMC	398,130
	By circumcision technique: Device-based VMMC	
	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	
	By follow-up status: Number of device based circumcision clients who returned at least once for follow-up care within 14 days of device placement	
PP_PREV_DSD	PP_PREV_DSD Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (DSD)	n/a
	Number of the target population	69,219



	who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	
	Total number of people in the target population	
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	
	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Denominator: Age/sex: 10-14 Male	
	Denominator: Age/sex: 15-19 Male	
	Denominator: Age/sex: 20-24 Male	
	Denominator: Age/sex: 25-49 Male	
	Denominator: Age/sex: 50+ Male	
	Denominator: Age/sex: 10-14 Female	
	Denominator: Age/sex: 15-19 Female	
	Denominator: Age/sex: 20-24 Female	
	Denominator: Age/sex: 25-49 Female	
	Denominator: Age/sex: 50+ Female	
	Service: PP known positive	
	Service: PP tested or referred for testing as part of program	



	New Client: New beneficiary	
	New Client: Returning Beneficiary	
	Aggregated Age/sex: <15 Male	39,782
	Aggregated Age/sex: 15+ Male	20,769
	Aggregated Age/sex: <15 Female	20,677
	Aggregated Age/sex: 15+ Female	13,844
KP_PREV_DSD	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)	n/a
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	45,088
	Total estimated number of key population in the catchment area	98,266
	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet	10,324



	the minimum standards required)	
	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	23,757
	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key	



	populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	11,007
	By key population type: Men who have sex with men who are sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	26,907
	By key population type: Transgender who are sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key	60,222



	population in the catchment area)	
	By key population type: Males who inject drugs (Male PWID) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)	11,137
	By Service: KP known status	
	By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program	
	By New Client Status: New beneficiary	
	By New Client Status: REturniong beneficiary within the current report period	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	4,030,962
	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	20,401
	Age/sex: 15-19 Male	17,892
	Age/sex: 20-24 Male	17,544
	Age/sex: 25-49 Male	31,487



	Age/sex: 50+ Male	6,630
	Age/sex: 5-9 Female	
	Age/sex: 10-14 Female	8,337
	Age/sex: 15-19 Female	33,509
	Age/sex: 20-24 Female	49,490
	Age/sex: 25-49 Female	80,771
	Age/sex: 50+ Female	8,418
	Test Result by Age and Sex: Positive: 10-14 Male	461
	Test Result by Age and Sex: Positive: 15-19 Male	864
	Test Result by Age and Sex: Positive: 20-24 Male	2,135
	Test Result by Age and Sex: Positive: 25-49 Male	9,440
	Test Result by Age and Sex: Positive: 50+ Male	2,012
	Test Result by Age and Sex: Positive: 10-14 Female	699
	Test Result by Age and Sex: Positive: 15-19 Female	2,919
	Test Result by Age and Sex: Positive: 20-24 Female	6,527
	Test Result by Age and Sex: Positive: 25-49 Female	15,603
	Test Result by Age and Sex: Positive: 50+ Female	2,297
	Test Result by Age and Sex: Negative: 10-14 Male	
	Test Result by Age and Sex: Negative: 15-19 Male	
	Test Result by Age and Sex: Negative: 20-24 Male	
	Test Result by Age and Sex:	



	Negative: 25-49 Male	
	Test Result by Age and Sex: Negative: 50+ Male	
	Test Result by Age and Sex: Negative: 10-14 Female	
	Test Result by Age and Sex: Negative: 15-19 Female	
	Test Result by Age and Sex: Negative: 20-24 Female	
	Test Result by Age and Sex: Negative: 25-49 Female	
	Test Result by Age and Sex: Negative: 50+ Female	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	456,059
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	900,151
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	414,111
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	2,261,022
	Test Result by Aggregated Age and Sex: Negative <15 Male	
	Test Result by Aggregated Age and Sex: Negative 15+ Male	
	Test Result by Aggregated Age and Sex: Negative <15 Female	
	Test Result by Aggregated Age and Sex: Negative 15+ Female	
	Test Result by Aggregated Age and Sex: Positive <15 Male	18,851
	Test Result by Aggregated Age	131,458



	and Sex: Positive 15+ Male	
	Test Result by Aggregated Age and Sex: Positive <15 Female	21,380
	Test Result by Aggregated Age and Sex: Positive 15+ Female	228,719
	Test Result by Age: Positive: <1	620
	Test Result by Age: Positive: 1-9	2,700
	Age/sex: <1	7,571
	Age/sex: 1-9	30,565
	Service Delivery Point (Community): Index testing	246,291
	Service Delivery Point (Community): Homebased testing	
	Service Delivery Point (Community): Mobile testing	
	Service Delivery Point (Community): Other	73,357
	Service Delivery Point (Community) by Age: <15 index testing	
	Service Delivery Point (Community) by Age: 15+ index testing	
	Service Delivery Point (Community) by Age: <15 homebased testing	
	Service Delivery Point (Community) by Age: 15+ homebased testing	
	Service Delivery Point (Community) by Age: <15 mobile testing	
	Service Delivery Point (Community) by Age: 15+ mobile testing	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Facility):	



	Inpatient	
	Service Delivery Point (Facility): Outpatient	1,537,257
	Service Delivery Point (Facility): Pediatric	47,315
	Service Delivery Point (Facility): Malnutrition facilities	
	Service Delivery Point (Facility): Other PITC	104,426
	Service Delivery Point (Facility): VCT	507,271
	Service Delivery Point (Facility): VMMC	417,520
	Service Delivery Point (Facility): PMTCT	833,135
	Service Delivery Point (Facility): TB Clinics	18,105
	Service Delivery Point (Facility): Index testing	246,285
	Service Delivery Point (Facility) by Age: <15 Inpatient	
	Service Delivery Point (Facility) by Age: >15 Inpatient	
	Service Delivery Point (Facility) by Age: <15 Outpatient	
	Service Delivery Point (Facility) by Age: >15 Outpatient	
	Service Delivery Point (Facility) by Age: <15 Pediatric	
	Service Delivery Point (Facility) by Age: >15 Pediatric	
	Service Delivery Point (Facility) by Age: <15 Malnutrition facilities	
	Service Delivery Point (Facility) by	



	Age: >15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: <15 Other PITC	
	Service Delivery Point (Facility) by Age: >15 Other PITC	
	Service Delivery Point (Facility) by Age: <15 VCT	
	Service Delivery Point (Facility) by Age: >15 VCT	
	Service Delivery Point (Facility) by Age: <15 VMMC	
	Service Delivery Point (Facility) by Age: >15 VMMC	
	Service Delivery Point (Facility) by Age: <15 PMTCT	
	Service Delivery Point (Facility) by Age: >15 PMTCT	
	Service Delivery Point (Facility) by Age: <15 TB Clinics	
	Service Delivery Point (Facility) by Age: >15 TB Clinics	
	Service Delivery Point (Facility) by Age: <15 Index testing	
	Service Delivery Point (Facility) by Age: >15 Index testing	
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	809,567
	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	



	Age/sex: 50+ Male	
	Age/sex: 5-9 Female	
	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Test Result by Age and Sex: Positive: 10-14 Male	
	Test Result by Age and Sex: Positive: 15-19 Male	
	Test Result by Age and Sex: Positive: 20-24 Male	
	Test Result by Age and Sex: Positive: 25-49 Male	
	Test Result by Age and Sex: Positive: 50+ Male	
	Test Result by Age and Sex: Positive: 10-14 Female	
	Test Result by Age and Sex: Positive: 15-19 Female	
	Test Result by Age and Sex: Positive: 20-24 Female	
	Test Result by Age and Sex: Positive: 25-49 Female	
	Test Result by Age and Sex: Positive: 50+ Female	
	Test Result by Age and Sex: Negative: 10-14 Male	
	Test Result by Age and Sex: Negative: 15-19 Male	
	Test Result by Age and Sex: Negative: 20-24 Male	
Test Result by Age and Sex:		



	Negative: 25-49 Male	
	Test Result by Age and Sex: Negative: 50+ Male	
	Test Result by Age and Sex: Negative: <1 Female	
	Test Result by Age and Sex: Negative: 10-14 Female	
	Test Result by Age and Sex: Negative: 15-19 Female	
	Test Result by Age and Sex: Negative: 20-24 Female	
	Test Result by Age and Sex: Negative: 25-49 Female	
	Test Result by Age and Sex: Negative: 50+ Female	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	46,209
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	99,318
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	68,614
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	595,426
	Test Result by Aggregated Age and Sex: Negative <15 Male	
	Test Result by Aggregated Age and Sex: Negative 15+ Male	
	Test Result by Aggregated Age and Sex: Negative <15 Female	
	Test Result by Aggregated Age and Sex: Negative 15+ Female	
	Test Result by Aggregated Age	1,338



	and Sex: Positive <15 Male	
	Test Result by Aggregated Age and Sex: Positive 15+ Male	11,914
	Test Result by Aggregated Age and Sex: Positive <15 Female	1,719
	Test Result by Aggregated Age and Sex: Positive 15+ Female	28,360
	Test Result by Age: Positive: <1	
	Test Result by Age: Positive: 1-9	
	Age/sex: <1	
	Age/sex: 1-9	
	Service Delivery Point (Community): Index testing	
	Service Delivery Point (Community): Homebased testing	
	Service Delivery Point (Community): Mobile testing	
	Service Delivery Point (Community): Other	
	Service Delivery Point (Community) by Age: <15 index testing	
	Service Delivery Point (Community) by Age: 15+ index testing	
	Service Delivery Point (Community) by Age: <15 homebased testing	
	Service Delivery Point (Community) by Age: 15+ homebased testing	
	Service Delivery Point (Community) by Age: <15 mobile testing	
	Service Delivery Point (Community) by Age: 15+ mobile testing	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Community)	



	by Age: <15 other	
	Service Delivery Point (Facility): Inpatient	
	Service Delivery Point (Facility): Outpatient	379,077
	Service Delivery Point (Facility): Pediatric	8,335
	Service Delivery Point (Facility): Malnutrition facilities	
	Service Delivery Point (Facility): Other PITC	31,422
	Service Delivery Point (Facility): VCT	103,101
	Service Delivery Point (Facility): VMMC	
	Service Delivery Point (Facility): PMTCT	282,614
	Service Delivery Point (Facility): TB Clinics	5,018
	Service Delivery Point (Facility): Index testing	
	Service Delivery Point (Facility) by Age: <15 Inpatient	
	Service Delivery Point (Facility) by Age: >15 Inpatient	
	Service Delivery Point (Facility) by Age: <15 Outpatient	
	Service Delivery Point (Facility) by Age: >15 Outpatient	
	Service Delivery Point (Facility) by Age: <15 Pediatric	
	Service Delivery Point (Facility) by Age: >15 Pediatric	
	Service Delivery Point (Facility) by	



	Age: <15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: >15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: <15 Other PITC	
	Service Delivery Point (Facility) by Age: >15 Other PITC	
	Service Delivery Point (Facility) by Age: <15 VCT	
	Service Delivery Point (Facility) by Age: >15 VCT	
	Service Delivery Point (Facility) by Age: <15 VMMC	
	Service Delivery Point (Facility) by Age: >15 VMMC	
	Service Delivery Point (Facility) by Age: <15 PMTCT	
	Service Delivery Point (Facility) by Age: >15 PMTCT	
	Service Delivery Point (Facility) by Age: <15 TB Clinics	
	Service Delivery Point (Facility) by Age: >15 TB Clinics	
	Service Delivery Point (Facility) by Age: <15 Index testing	
	Service Delivery Point (Facility) by Age: >15 Index testing	
	TB_STAT_DSD	TB_STAT_DSD Percentage of registered new and relapsed TB cases with documented HIV status.
Number of registered new and relapsed TB cases with		72,292



	documented HIV status, during the reporting period.	
	Total number of registered new and relapsed TB cases, during the reporting period.	72,292
	Age/Sex: <1 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: 1-9 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 50+ (Numerator: Number of registered new and	



	relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	13
	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with	25,327



	documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	20
	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	46,951
	Result: Known HIV positive at service entry	
	Result: New HIV positive	
	Result: HIV Negative	
	Age/Sex: <1 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: 1-9 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 20-24 (Denominator: Total number of registered new and relapsed TB	



	cases, during the reporting period.)	
	Age/Sex: Male 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 50+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 50+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Denominator: Total number of	



	registered new and relapsed TB cases, during the reporting period)	
	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
TB_STAT_TA	TB_STAT_TA Percentage of registered new and relapsed TB cases with documented HIV status.	n/a
	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	14,253
	Total number of registered new and relapsed TB cases, during the reporting period.	14,253
	Age/Sex: <1 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: 1-9 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	



	Age/Sex: Male 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 25-49	



	(Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	4,990
	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	9,266
	Result: Known HIV positive at service entry	
	Result: New HIV positive	
	Result: HIV negative	
	Age/Sex: <1 (Denominator: Total number of registered new and	



	relapsed TB cases, during the reporting period)	
	Age/Sex: 1-9 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 50+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Female 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Female 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Female 20-24	



	(Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Female 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
GEND_GBV_DSD	Number of people receiving post-GBV care	28,316
	Age/Sex: <10 Male	64
	Age/Sex: 10-14 Male	171
	Age/Sex: 15-17 Male	
	Age/Sex: 18-19 Male	
	Age/Sex: 20-24 Male	171
	Age/Sex: 25-49 Male	64
	Age/Sex: 50+ Male	
	Age/Sex: <10 Female	317
	Age/Sex: 10-14 Female	1,445
	Age/Sex: 15-17 Female	
	Age/Sex: 18-19 Female	
	Age/Sex: 20-24 Female	1,445
	Age/Sex: 25-49 Female	1,155
	Age/Sex: 50+ Female	
	Sum of Age/Sex Disaggregates	1,997
	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	21,338
	By type of service: Sexual Violence (Post-Rape Care)	7,188
By PEP service provision (related to sexual violence services provided)	5,329	
Age/Sex: 15-19 Female	1,445	



	Age/Sex: 15-19 male	171
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	420,840
	Age/Sex: 10-14 Male	
	Age/Sex: 15-17 Male	
	By: Age/sex: Male 18-24	
	By: Age/sex: Male 25+	
	Age/Sex: 18+ Male	8,418
	Age/Sex: 10-14 Female	
	Age/Sex: 15-17 Female	
	By: Age/sex: 18-24 Female	
	By: Age/sex: 25+ Female	
	Age/Sex: 18+ Female	16,834
	Sum of Age/Sex disaggregates	25,252
	Required only for DREAMS countries - By service, age and sex: Education Support Female <1	337
	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	2,252
	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	901
	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	337
	Required only for DREAMS countries - By service, age and sex: Education Support Female	225



	25+	
	Required only for DREAMS countries - By service, age and sex: Education Support Male <1	337
	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	2,138
	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	788
	Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24	225
	Required only for DREAMS countries - By service, age and sex: Education Support Male 25+	113
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female <1	152
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	1,010
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	404
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	152
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs	101



	Female 25+	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male <1	152
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14	958
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17	354
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24	101
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 25+	51
	Required only for DREAMS countries - By service, age and sex: Social Protection Female <1	559
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	3,728
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	1,491
	Required only for DREAMS countries - By service, age and sex: Social Protection Female	559



	18-24	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 25+	372
	Required only for DREAMS countries - By service, age and sex: Social Protection Male <1	559
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14	3,541
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17	1,304
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 18-24	372
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 25+	187
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female <1	58
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14	389
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	154
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	58



	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+	38
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male <1	58
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 10-14	369
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17	135
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24	38
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 25+	20
	Required only for DREAMS countries - By service, age and sex: Other Services Female <1	58
	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	389
	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	154
	Required only for DREAMS countries - By service, age and	58



	sex: Other Services Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 25+	38
	Required only for DREAMS countries - By service, age and sex: Other Services Male <1	58
	Required only for DREAMS countries - By service, age and sex: Other Services Male 10-14	369
	Required only for DREAMS countries - By service, age and sex: Other Services Male 15-17	135
	Required only for DREAMS countries - By service, age and sex: Other Services Male 18-24	38
	Required only for DREAMS countries - By service, age and sex: Other Services Male 25+	20
	Age/Sex: <1	
	Age/Sex: 1-9	
	Required only for DREAMS countries - By service, age and sex: Education Support 1-9 Male	1,801
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 1-9	807
	Required only for DREAMS countries - By service, age and sex: Social Protection Programs Male 1-9	2,981
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male	310



	1-9	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 1-9	310
	Program Completion: Active	
	Program Completion: Graduation	
	Program Completion: Transferred	
	Program Completion: Exited without graduation	
	By Aggregated Age/Sex: <18 Male	193,586
	By Aggregated Age/Sex: 18+ Male	
	By Aggregated Age/Sex: <18 Female	202,002
	By Aggregated Age/Sex: 18+ Female	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 1-9	1,801
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 1-9	807
	Required only for DREAMS countries - By service, age and sex: Social Protection Programs Female 1-9	2,981
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 1-9	310
	Required only for DREAMS countries - By service, age and sex: Other Services Female 1-9	310
TB_ART_DSD	TB_ART_DSD Percentage of	n/a



	HIV-positive new and relapsed registered TB cases on ART during TB treatment	
	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	39,895
	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	39,895
	Age/Sex: >1 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during	



	the reporting period)	
	Age/Sex: Male 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: The number of registered new and relapse TB	



	cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	7
	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	13,970
	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on	10



	ART during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	25,917
	On ART: Already on ART	
	On ART: New on ART	
	Age/Sex: >1 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting	



	period)	
	Age/Sex: Male 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 20-24	



	(Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female <15 (Denominator: The number of	



	registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
TB_ART_TA	TB_ART_TA Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	n/a
	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	5,213
	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	5,213
	Age/Sex: <1 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on	



	ART during TB treatment during the reporting period)	
	Age/Sex: Male 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 10-14 (Numerator: The number of registered new and relapse TB cases with documented	



	HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during	



	the reporting period)	
	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1,827
	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	3,392
	On ART: Already on ART	
	On ART: New on ART	
	Age/Sex: <1 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	



	Age/Sex: Male 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 10-14 (Denominator: The number of	



	registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB	



	cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	998,694
	Screened for TB by Age/Sex:<15 Male	46,477
	Screened for TB by Age/Sex: 15+ Male	317,924
	Screened for TB by Age/Sex:<15 Female	46,513



	Screened for TB by Age/Sex: 15+ Female	588,173
	Screen Result: Screened Positive for TB	80,038
	TB Positive by Age/Sex: <15 Male	
	TB Positive by Age/Sex: 15+ Male	
	TB Positive by Age/Sex: <15 Female	
	TB Positive by Age/Sex: 15+ Female	
	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	703
	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	562
	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	141
	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	
TB_SCREENDX_TA	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	117,979
	Screened for TB by Age/Sex: <15 Male	4,821
	Screened for TB by Age/Sex: 15+ Male	37,942
	Screened for TB by Age/Sex: <15 Female	4,821
	Screened for TB by Age/Sex: 15+ Female	70,465
	Screen Results: Screened Positive for TB	9,438



	TB Positive by Age/Sex: <15 Male	
	TB Positive by Age/Sex: 15+ Male	
	TB Positive by Age/Sex: <15 Female	
	TB Positive by Age/Sex: 15+ Female	
	[Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	
	[Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only	
	[Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	
	[Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert)	
PMTCT_EID_DSD	PMTCT_EID_DSD Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (DSD)	n/a
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	
	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	
	By infants who received a virologic test within 2 months of birth	55,696
	By infants who received their first virologic HIV test between 2 and 12 months of age	24,971
	Sum of Infant Age disaggregates	80,667



	By infants with a positive virologic test result within 12 months of birth	
	Number of infants with a positive virological test result within 2 months of birth	2,774
	Number of infants with a negative virological test result within 2 months of birth	
	Number of infants with a positive virological test result between 2 and 12 months of birth	
	Number of infants with a negative virological test result between 2 and 12 months of birth	
	Number of infants with a positive virological test result within 12 months of birth	2,003
PMTCT_EID_TA	PMTCT_EID_TA Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (TA)	n/a
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	
	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	
	By infants who received a virologic test within 2 months of birth	6,333
	By infants who received their first virologic HIV test between 2 and 12 months of age	2,849
	Sum of Infant Age disaggregates	9,182



	By infants with a positive virologic test result within 12 months of birth	
	Number of infants with a positive virological test result within 2 months of birth	314
	Number of infants with a negative virological test result within 2 months of birth	
	Number of infants with a positive virological test result between 2 and 12 months of birth	
	Number of infants with a negative virological test result between 2 and 12 months of birth	
	Number of infants with a positive virological test result within 12 months of birth	229
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	884,618
	Age/Sex: 15-19 Male	3,149
	Age/Sex: 15-19 Female	4,658
	Age/Sex: 20+ Female	
	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	36,772
	Aggregated Age/Sex: 15+ Male	286,599
	Aggregated Age/Sex: <15 Female	36,889
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	524,693
	Sum of Aggregated Age/Sex <15	73,661
	Sum of Aggregated Age/Sex 15+	811,292
	Sum of Aggregated Age/Sex disaggregates	884,953



	Age/Sex: <1	4,061
	Age/Sex: <1-9	6,984
	Age/Sex: 10-14 Male	1,499
	Age/Sex: 10-14 Female	1,499
	Aggregated Age/Sex: 1-14 Male	
	Sum of Aggregated Age/Sex (<1 and 1-14) <15	
	Age/Sex: 20-24 Male	8,280
	Age/Sex: 25-49 Male	29,978
	Age/Sex: 50+ Male	6,882
	Age/Sex: 20-24 Female	10,671
	Age/Sex: 25-49 Female	24,309
	Age/Sex: 50+ Female	3,870
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	96,451
	Age/Sex: <1 Male	
	Age/Sex: 1-4 Male	
	Age/Sex: 5-14 Male	
	Age/Sex: 15-19 Male	
	Age/Sex: 20+ Male	
	Age/Sex: <1 Female	
	Age/Sex: 1-4 Female	
	Age/Sex: 5-14 Female	
	Age/Sex: 15-19 Female	
	Age/Sex: 20+ Female	
	Sum of Age/Sex disaggregations	
	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	4,696
	Aggregated Age/Sex: 1-14 Male	
	Aggregated Age/Sex: 15+ Male	30,491



	Aggregated Age/Sex: <15 Female	4,696
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	56,633
	Sum of Aggregated Age/Sex <15	9,392
	Sum of Aggregated Age/Sex 15+	87,124
	Sum of Aggregated Age/Sex disaggregates	96,516
	Age/Sex: <1	498
	Age/Sex: 1-9	
	Age/Sex: 10-14 Male	
	Age/Sex: 10-14 Female	
	Sum of Aggregated Age/Sex (<1 and 1-14) <15	
	Age/Sex: 20-24 Male	
	Age/Sex: 25-49 Male	
	Age/Sex: 50+ Male	
	Age/Sex: 20-24 Female	
	Age/Sex: 25-49 Female	
	Age/Sex: 50+ Female	
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	313,844
	By Age/Sex: <1	4,061
	By Age/Sex: 1-9	3,682
	By Age/Sex: 10-14 Male	382
	By Age/Sex: 15-19 Male	1,128
	By Age/Sex: 20-24 Male	2,969
	By Age/Sex: 25-49 Male	10,749
	By Age/Sex: 50+ Male	2,470
	By Age/Sex: 10-14 Female	777
	By Age/Sex: 15-19 Female	1,670
	By Age/Sex: 20-24 Female	3,827



	By Age/Sex: 25-49 Female	8,716
	By Age/Sex: 50+ Female	1,392
	Sum of Age/Sex disaggregates	34,080
	Aggregated Grouping by Age: <1	
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <15 Male	180,940
	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	99,419
	Aggregated Grouping by Age/Sex: <1 Female	
	Aggregated Grouping by Age/Sex: <15 Female	16,904
	Aggregated Grouping by Age/Sex: 15+ Female	16,891
	Sum of Aggregated Age/Sex disaggregates	314,154
	Pregnancy status	
	Breastfeeding status	
	Aggregated Grouping by Age/Sex: 1-14 Female	
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	25,805
	By Age/Sex: <1	
	By Age/Sex: 1-9	
	By Age/Sex: <1 Male	
	By Age/Sex: 1-4 Male	
	By Age/Sex: 5-9 Male	
	By Age/Sex: 10-14 Male	



	By Age/Sex: 15-19 Male	
	By Age/Sex: 20-24 Male	
	By Age/Sex: 25-49 Male	
	By Age/Sex: 50+ Male	
	By Age/Sex: <1 Female	
	By Age/Sex: 1-4 Female	
	By Age/Sex: 5-9 Female	
	By Age/Sex: 10-14 Female	
	By Age/Sex: 15-19 Female	
	By Age/Sex: 20-24 Female	
	By Age/Sex: 25-49 Female	
	By Age/Sex: 50+ Female	
	Sum of Age/Sex disaggregates	
	Aggregated Grouping by Age: <1	498
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <15 Male	14,639
	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	7,885
	Aggregated Grouping by Age: <1 Female	
	Aggregated Grouping by Age/Sex: <15 Female	1,666
	Aggregated Grouping by Age/Sex: 1-14 Female	
	Aggregated Grouping by Age/Sex: 15+ Female	1,666
	Sum of Aggregated Age/Sex disaggregates	25,856
	Pregnancy status	



	Breastfeeding status	
TX_PVLS_DSD	TX_PVLS_DSD Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	n/a
	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	203,516
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	271,365
	Numerator: Indication: Routine	36,711
	Numerator: Indication: Targeted	166,806
	Numerator: Preg/BF by Indication: Pregnant Routine	
	Numerator: Preg/BF by Indication: Breastfeeding Routine	
	Numerator: Preg/BF by Indication: Pregnant Targeted	
	Numerator: Preg/BF by Indication: Breastfeeding Targeted	
	Numerator: Age/Sex by Indication: <1 Routine	
	Numerator: Age/Sex by Indication: 1-9 Routine	
	Numerator: Age/Sex by Indication: 10-14 Male Routine	



	Numerator: Age/Sex by Indication: 15-19 Male Routine	
	Numerator: Age/Sex by Indication: 20-24 Male Routine	
	Numerator: Age/Sex by Indication: 25-49 Male Routine	
	Numerator: Age/Sex by Indication: 50+ Male Routine	
	Numerator: Age/Sex by Indication: 10-14 Female Routine	
	Numerator: Age/Sex by Indication: 15-19 Female Routine	
	Numerator: Age/Sex by Indication: 20-24 Female Routine	
	Numerator: Age/Sex by Indication: 25-49 Female Routine	
	Numerator: Age/Sex by Indication: 50+ Female Routine	
	Numerator: Age/Sex by Indication: <1 Targeted	
	Numerator: Age/Sex by Indication: 1-9 Targeted	
	Numerator: Age/Sex by Indication: 10-14 Male Targeted	
	Numerator: Age/Sex by Indication: 15-19 Male Targeted	
	Numerator: Age/Sex by Indication: 20-24 Male Targeted	
	Numerator: Age/Sex by Indication: 25-49 Male Targeted	
	Numerator: Age/Sex by Indication: 50+ Male Targeted	
	Numerator: Age/Sex by Indication: 10-14 Female Targeted	



	Numerator: Age/Sex by Indication: 15-19 Female Targeted	
	Numerator: Age/Sex by Indication: 20-24 Female Targeted	
	Numerator: Age/Sex by Indication: 25-49 Female Targeted	
	Numerator: Age/Sex by Indication: 50+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Denominator: Indication: Routine	48,936
	Denominator: Indication: Targeted	222,429
	Denominator: Preg/BF by Indication: Pregnant Routine	
	Denominator: Preg/BF by Indication: Breastfeeding Routine	
	Denominator: Preg/BF by Indication: Pregnant Targeted	
	Denominator: Preg/BF by Indication: Breastfeeding Targeted	



	Denominator: Age/Sex by Indication: <1 Routine	
	Denominator: Age/Sex by Indication: 1-9 Routine	
	Denominator: Age/Sex by Indication: 10-14 Male Routine	
	Denominator: Age/Sex by Indication: 15-19 Male Routine	
	Denominator: Age/Sex by Indication: 20-24 Male Routine	
	Denominator: Age/Sex by Indication: 25-49 Male Routine	
	Denominator: Age/Sex by Indication: 50+ Male Routine	
	Denominator: Age/Sex by Indication: 10-14 Female Routine	
	Denominator: Age/Sex by Indication: 15-19 Female Routine	
	Denominator: Age/Sex by Indication: 20-24 Female Routine	
	Denominator: Age/Sex by Indication: 25-49 Female Routine	
	Denominator: Age/Sex by Indication: 50+ Female Routine	
	Denominator: Age/Sex by Indication: <1 Targeted	
	Denominator: Age/Sex by Indication: 1-9 Targeted	
	Denominator: Age/Sex by Indication: 10-14 Male Targeted	
	Denominator: Age/Sex by Indication: 15-19 Male Targeted	
	Denominator: Age/Sex by Indication: 20-24 Male Targeted	



	Denominator: Age/Sex by Indication: 25-49 Male Targeted	
	Denominator: Age/Sex by Indication: 50+ Male Targeted	
	Denominator: Age/Sex by Indication: 10-14 Female Targeted	
	Denominator: Age/Sex by Indication: 15-19 Female Targeted	
	Denominator: Age/Sex by Indication: 20-24 Female Targeted	
	Denominator: Age/Sex by Indication: 25-49 Female Targeted	
	Denominator: Age/Sex by Indication: 50+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Numerator Aggregated Age/Sex: <15 Male	111,636
	Numerator Aggregated Age/Sex: 15+ Male	60,122



	Numerator Aggregated Age/Sex: <15 Female	16,062
	Numerator Aggregated Age/Sex: 15+ Female	16,062
	Denominator Aggregated Age/Sex: <15 Male	21,361
	Denominator Aggregated Age/Sex: 15+ Male	80,160
	Denominator Aggregated Age/Sex: <15 Female	21,361
	Denominator Aggregated Age/Sex: 15+ Female	148,856
TX_PVLS_TA	TX_PVLS_TA Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	n/a
	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	24,560
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	32,756
	Numerator: Age/Sex by Indication: <1 Routine	
	Numerator: Age/Sex by Indication: <1 Targeted	
	Numerator: Age/Sex by Indication:	
	Numerator: Age/Sex by Indication:	



	1-9 Routine	
	Numerator: Age/Sex by Indication: 1-9 Targeted	
	Numerator: Age/Sex by Indication: 10-14 Female Routine	
	Numerator: Age/Sex by Indication: 10-14 Female Targeted	
	Numerator: Age/Sex by Indication: 10-14 Male Routine	
	Numerator: Age/Sex by Indication: 10-14 Male Targeted	
	Numerator: Age/Sex by Indication: 15-19 Female Routine	
	Numerator: Age/Sex by Indication: 15-19 Female Targeted	
	Numerator: Age/Sex by Indication: 15-19 Male Routine	
	Numerator: Age/Sex by Indication: 15-19 Male Targeted	
	Numerator: Age/Sex by Indication: 20-24 Female Routine	
	Numerator: Age/Sex by Indication: 20-24 Female Targeted	
	Numerator: Age/Sex by Indication: 20-24 Male Routine	
	Numerator: Age/Sex by Indication: 20-24 Male Targeted	
	Numerator: Age/Sex by Indication: 25-49 Female Routine	
	Numerator: Age/Sex by Indication: 25-49 Female Targeted	
	Numerator: Age/Sex by Indication: 25-49 Male Routine	
	Numerator: Age/Sex by Indication:	



	25-49 Male Targeted	
	Numerator: Age/Sex by Indication: 50+ Female Routine	
	Numerator: Age/Sex by Indication: 50+ Female Targeted	
	Numerator: Age/Sex by Indication: 50+ Male Routine	
	Numerator: Age/Sex by Indication: 50+ Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Numerator: Indication: Routine	4,493
	Numerator: Indication: Targeted	20,067
	Numerator: Preg/BF by Indication: Breastfeeding Routine	
	Numerator: Preg/BF by Indication: Breastfeeding Targeted	
	Numerator: Preg/BF by Indication: Pregnant Routine	
	Numerator: Preg/BF by Indication:	



	Pregnant Targeted	
	Denominator: Indication: Routine	5,981
	Denominator: Indication: Targeted	26,775
	Denominator: Age/Sex by Indication: <1 Routine	
	Denominator: Age/Sex by Indication: <1 Targeted	
	Denominator: Age/Sex by Indication: 1-9 Routine	
	Denominator: Age/Sex by Indication: 1-9 Targeted	
	Denominator: Age/Sex by Indication: 10-14 Female Routine	
	Denominator: Age/Sex by Indication: 10-14 Female Targeted	
	Denominator: Age/Sex by Indication: 10-14 Male Routine	
	Denominator: Age/Sex by Indication: 10-14 Male Targeted	
	Denominator: Age/Sex by Indication: 15-19 Female Routine	
	Denominator: Age/Sex by Indication: 15-19 Female Targeted	
	Denominator: Age/Sex by Indication: 15-19 Male Routine	
	Denominator: Age/Sex by Indication: 15-19 Male Targeted	
	Denominator: Age/Sex by Indication: 20-24 Female Routine	
	Denominator: Age/Sex by Indication: 20-24 Female Targeted	
	Denominator: Age/Sex by Indication: 20-24 Male Routine	
	Denominator: Age/Sex by	



	Indication: 20-24 Male Targeted	
	Denominator: Age/Sex by Indication: 25-49 Female Routine	
	Denominator: Age/Sex by Indication: 25-49 Female Targeted	
	Denominator: Age/Sex by Indication: 25-49 Male Routine	
	Denominator: Age/Sex by Indication: 25-49 Male Targeted	
	Denominator: Age/Sex by Indication: 50+ Female Routine	
	Denominator: Age/Sex by Indication: 50+ Female Targeted	
	Denominator: Age/Sex by Indication: 50+ Male Routine	
	Denominator: Age/Sex by Indication: 50+ Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Denominator: Preg/BF by	



	Indication: Breastfeeding Routine	
	Denominator: Preg/BF by Indication: Breastfeeding Targeted	
	Denominator: Preg/BF by Indication: Pregnant Routine	
	Denominator: Preg/BF by Indication: Pregnant Targeted	
	Numerator Aggregated Age/Sex: <15 Male	13,343
	Numerator Aggregated Age/Sex: 15+ Male	7,185
	Numerator Aggregated Age/Sex: <15 Female	2,049
	Numerator Aggregated Age/Sex: 15+ Female	2,049
	Denominator Aggregated Age/Sex: <15 Male	2,723
	Denominator Aggregated Age/Sex: 15+ Male	9,582
	Denominator Aggregated Age/Sex: <15 Female	2,723
	Denominator Aggregated Age/Sex: 15+ Female	17,796
TX_RET_DSD	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	n/a
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	255,271
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those	330,951



	who have died, those who have stopped ART, and those lost to follow-up	
	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	484
	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,849
	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	240
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	667
	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,747
	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6,327
	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,454
	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after	490



	initiating ART	
	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,135
	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,891
	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	11,141
	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,776
	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	605
	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,310
	Age/Sex: 10-14 Male (Denominator: Total number of	307



	adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	828
	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,183
	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	7,907
	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	1,818



	stopped ART, and those lost to follow-up)	
	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	612
	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,669
	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6,115
	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	13,931
	Age/Sex: 50+ Female (Denominator: Total number of	2,217



	adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Numerator by Status: Pregnant	
	Numerator by Status: Breastfeeding	
	Denominator by Status: Pregnant	
	Denominator by Status:	



	Breastfeeding	
	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	151,180
	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	83,020
	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	10,719
	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	10,709
	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	196,042
	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and	107,583



	those lost to follow-up)	
	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	13,859
	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	13,846
TX_RET_TA	TX_RET_TA Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	n/a
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	22,826
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	32,609
	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 1-9 (Numerator: Number	



	of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 20-24 Female (Numerator: Number of adults and	



	children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: <1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 15-19 Male (Denominator: Total number of	



	<p>adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died,</p>	



	those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: <15 (Numerator: Number of adults and children who	



	are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Numerator by Status: Pregnant	
	Numerator by Status: Breastfeeding	
	Denominator by Status: Pregnant	
	Denominator by Status: Breastfeeding	
	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	12,912
	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and	6,953



	children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,513
	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,513
	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	18,435
	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	9,927
	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and	2,152



	those lost to follow-up)	
	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,152
LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	
	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	127
	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	114
	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	115
	CD4: Number of laboratories that perform this testing	191
	CD4: Number of laboratories that participate in this PT program	179
	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	170
	Early infant diagnostics: Number of laboratories that perform this testing	5



	Early infant diagnostics: Number of laboratories that participate in this PT program	5
	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	5
	HIV viral load: Number of laboratories that perform this testing	8
	HIV viral load: Number of laboratories that participate in this PT program	8
	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	8
	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	344
	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	157
	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	133
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	59
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	59
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that	56



	achieve acceptable successful passing criteria in this PT program	
	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	3
	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	3
	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	3
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	769
	By Graduates: Doctors	
	By Graduates: Nurses	339
	By Graduates: Midwives	
	By Graduates: Social service workers	120
	By Graduates: Laboratory professionals	65
	By Graduates: Other	245
	Sum of Graduates disaggreagtes	769
INVS_COMD	PEPFAR resources used for HIV-program related commodities: planned & purchased in the last 12 months by Implementing Partner	
	Number of HIV Test Kits purchased	9,650,000
	Number of HIV CD4 Reagents purchased	563,602

Approved



	Number of Condoms purchased	0
	Number of HIV Viral Load Reagents purchased	412,500
	Number of HIV ARVs purchased	
	Number of Second Line HIV ARVs purchased	
	HIV Test Kits: Dollars planned (COP)/ spent (Actual)	9,742,728
	HIV CD4 Tests: Dollars planned (COP)/ spent (Actual)	
	HIV Viral Load: Dollars planned (COP)/ spent (Actual)	
	Condoms: Dollars planned (COP)/ spent (Actual)	
	HIV ARVs: Dollars planned (COP)/ spent (Actual)	



Partners and Implementing Mechanisms

Partner List

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
7314	University Research Corporation, LLC	Private Contractor	U.S. Agency for International Development	GHP-State	0
7315	FHI 360	NGO	U.S. Agency for International Development	GHP-State	0
7328	University of North Carolina at Chapel Hill, Carolina Population Center	University	U.S. Agency for International Development	GHP-State	492,210
7387	Arquiplan, Lda	NGO	U.S. Agency for International Development	GHP-State	0
7388	Técnicos Construtores (TEC), Lda	Private Contractor	U.S. Agency for International Development	GHP-State	0
9564	American Society of Clinical Pathology	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,395,000
9568	American Society for Microbiology	Private Contractor	U.S. Department of Health and Human Services/Centers	GHP-State	1,460,645



			for Disease Control and Prevention		
9570	U.S. Department of State	Other USG Agency	U.S. Department of State/Bureau of African Affairs	GHP-State	435,000
9725	American International Health Alliance Twinning Center	NGO	U.S. Department of Health and Human Services/Health Resources and Services Administration	GHP-State	340,340
9811	Vanderbilt University	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	26,903,259
9818	Association of Public Health Laboratories	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,581,183
9856	Ministry of Health, Mozambique	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	200,000
10971	U.S. Department of Defense	Other USG Agency	U.S. Department of Defense	GHP-State	0



	(Defense)				
11463	U.S. Peace Corps	Other USG Agency	U.S. Peace Corps	GHP-State	112,000
11580	JHPIEGO	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	22,674,145
12149	World Vision International	FBO	U.S. Agency for International Development	GHP-State	1,125,165
12150	Management Sciences for Health	NGO	U.S. Agency for International Development	GHP-State	0
12159	United Nations Development Programme	Multi-lateral Agency	U.S. Agency for International Development	GHP-State	0
12165	Health Alliance International	NGO	U.S. Agency for International Development	GHP-State	980,526
12168	Pathfinder International	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	2,787,884
12619	American Association of Blood Banks	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and	GHP-State	490,000



			Prevention		
12648	United States Pharmacopeia	Private Contractor	U.S. Agency for International Development	GHP-State	0
12665	Provincial Directorate of Health, Cabo Delgado	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	388,710
12681	JEMBI	Private Contractor	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	875,000
12702	University of California at San Francisco	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	5,130,913
12998	Provincial Directorate of Health, Maputo	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	213,226
13022	FHI 360	NGO	U.S. Agency for International Development	GHP-State	33,510,895
13160	Provincial	Host Country	U.S. Department	GHP-State	677,419



	Directorate of Health, Zambesia	Government Agency	of Health and Human Services/Centers for Disease Control and Prevention		
13313	Regional Procurement Support Office/Frankfurt	Other USG Agency	U.S. Department of State/Bureau of African Affairs	GHP-State	1,184,003
13583	Columbia University Mailman School of Public Health	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	18,640,588
13654	TBD	TBD	Redacted	Redacted	Redacted
13661	TBD	TBD	Redacted	Redacted	Redacted
13668	Fundacao ARIEL Contra a SIDA Pediatrica	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	17,161,676
13776	Center for Collaboration in Health	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	16,873,526
13784	Instituto Nacional de Saude	Host Country Government Agency	U.S. Department of Health and Human	GHP-State	4,394,308



			Services/Centers for Disease Control and Prevention		
14597	DevResults	Private Contractor	U.S. Agency for International Development	GHP-State	76,000
14598	Futures Group	Private Contractor	U.S. Agency for International Development	GHP-State	0
14639	EUROSIS - Consultoria e Formacao em Gestao, Lda	Private Contractor	U.S. Agency for International Development	GHP-State	0
14644	Resolve Solution Partners (PTY), Ltd	Private Contractor	U.S. Agency for International Development	GHP-State	0
14647	ASNA Construções & Engenharia	Private Contractor	U.S. Agency for International Development	GHP-State	0
14650	TBD	TBD	Redacted	Redacted	Redacted
14652	Columbia University Mailman School of Public Health	University	U.S. Agency for International Development	GHP-State	0
14670	Foundation for Community Development, Mozambique	NGO	U.S. Agency for International Development	GHP-State	0
14732	FHI 360	NGO	U.S. Agency for International Development	GHP-State	0
14739	World Education	NGO	U.S. Agency for International Development	GHP-State	1,554,206



14748	United Nations Children's Fund	Multi-lateral Agency	U.S. Agency for International Development	GHP-State	300,000
14789	Elizabeth Glaser Pediatric AIDS Foundation	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	21,895,240
14792	ISCISA- Superior Institution of Health Sciences	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
14806	U.S. Department of State	Other USG Agency	U.S. Department of State/Bureau of African Affairs	GHP-State	425,000
14822	TBD	TBD	Redacted	Redacted	Redacted
16052	University of California at San Francisco	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	422,721
16671	TBD	TBD	Redacted	Redacted	Redacted
16802	Provincial Directorate of Health, Inhambane	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	145,484



16879	World Food Program	Multi-lateral Agency	U.S. Agency for International Development	GHP-State	2,000,000
16900	FHI 360	NGO	U.S. Agency for International Development	GHP-State	0
16998	Provincial Directorate of Health, Gaza	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	388,710
16999	Provincial Directorate of Health, Nampula	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	273,226
17044	Ministry of Health, Mozambique	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	4,251,674
17104	ICF Macro	Private Contractor	U.S. Agency for International Development	GHP-State	350,000
17169	John Snow Inc (JSI)	Implementing Agency	U.S. Agency for International Development	GHP-State	762,828
17171	N'WETI - Comunicação para Saúde	NGO	U.S. Agency for International Development	GHP-State	0



17259	JEMBI	Private Contractor	U.S. Agency for International Development	GHP-State	350,000
17260	REENCONTRO - Associação Moçambicana Para Apoio e Desenvolvimento da Criança Orfã	NGO	U.S. Agency for International Development	GHP-State	0
17261	Associação Nacional dos Enfermeiros de Mocambique (ANEMO)	NGO	U.S. Agency for International Development	GHP-State	0
17567	National Alliance of State and Territorial AIDS Directors	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,004,105
17571	Columbia University Mailman School of Public Health	University	U.S. Department of Health and Human Services/Health Resources and Services Administration	GHP-State	0
17652	University of California	University	U.S. Agency for International Development	GHP-State	0
17723	JHPIEGO	University	U.S. Department of Defense	GHP-State	2,046,616
18099	FHI 360	NGO	U.S. Agency for International Development	GHP-State	0



18100	Ajuda de Desenvolvimento de Povo para Povo	NGO	U.S. Agency for International Development	GHP-State	0
18101	JHPIEGO	University	U.S. Agency for International Development	GHP-State	500,000
18102	TBD	TBD	Redacted	Redacted	Redacted
18103	FHI 360	NGO	U.S. Agency for International Development	GHP-State	3,091,965
18104	TBD	TBD	Redacted	Redacted	Redacted
18108	JHPIEGO	University	U.S. Department of Defense	GHP-State	2,094,727
18110	African Health Profession Regulatory Collaborative for Nurses and Midwives	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
18122	TBD	TBD	Redacted	Redacted	Redacted
18123	Counterpart International	NGO	U.S. Agency for International Development	GHP-State	150,000
18275	John Snow Inc (JSI)	Implementing Agency	U.S. Agency for International Development	GHP-State	5,914,191
18280	TBD	TBD	Redacted	Redacted	Redacted
18282	Global Health Supply Chain Program	Private Contractor	U.S. Agency for International Development	GHP-State	57,200,196
18311	TBD	TBD	Redacted	Redacted	Redacted
18312	Program for Appropriate	NGO	U.S. Agency for International	GHP-State	0



	Technology in Health		Development		
18319	Associação Para o Desenvolvimento Sócio-Económico	NGO	U.S. Agency for International Development	GHP-State	816,268
18336	Catholic Relief Services	FBO	U.S. Agency for International Development	GHP-State	700,000
18366	Abt Associates	Private Contractor	U.S. Agency for International Development	GHP-State	0
18367	Right To Care, South Africa	NGO	U.S. Agency for International Development	GHP-State	1,204,662
18368	Johns Hopkins University Bloomberg School of Public Health	University	U.S. Agency for International Development	GHP-State	1,035,394
18372	Central de Medicamentos e Artigos Medicos (CMAM)	Implementing Agency	U.S. Agency for International Development	GHP-State	480,526
18373	Palladium Group	NGO	U.S. Agency for International Development	GHP-State	150,000
18429	TBD	TBD	Redacted	Redacted	Redacted
18454	African Society for Laboratory Medicine	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	240,000
18455	TBD	TBD	Redacted	Redacted	Redacted

Approved



18456	FHI 360	NGO	U.S. Agency for International Development	GHP-State	0
18466	Population Council	NGO	U.S. Agency for International Development	GHP-State	0
18478	TBD	TBD	Redacted	Redacted	Redacted



Implementing Mechanism(s)

Implementing Mechanism Details

Mechanism ID: 7314	Mechanism Name: ASSIST (Applying Science to Strengthen and Improve Systems)
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: University Research Corporation, LLC	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	7314		
Mechanism Name:	ASSIST (Applying Science to Strengthen and Improve Systems)		
Prime Partner Name:	University Research Corporation, LLC		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0

Implementing Mechanism Indicator Information



(No data provided.)

Implementing Mechanism Details

Mechanism ID: 7315	Mechanism Name: Food and Nutrition Technical Assistance III (FANTA-III)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	7315		
Mechanism Name:	Food and Nutrition Technical Assistance III (FANTA-III)		
Prime Partner Name:	FHI 360		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0

Implementing Mechanism Indicator Information



(No data provided.)

Implementing Mechanism Details

Mechanism ID: 7328	Mechanism Name: MEASURE EVALUATION Phase IV
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: University of North Carolina at Chapel Hill, Carolina Population Center	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 492,210	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 492,210	
Funding Source	Funding Amount
GHP-State	492,210

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	7328		
Mechanism Name:	MEASURE EVALUATION Phase IV		
Prime Partner Name:	University of North Carolina at Chapel Hill, Carolina Population Center		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	192,210	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount

Approved



Governance and Systems	HVSI	300,000	0
------------------------	------	---------	---

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 7387	Mechanism Name: Oversight for 16 Type II RHC & 3 Warehouses
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Arquiplan, Lda	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	7387		
Mechanism Name:	Oversight for 16 Type II RHC & 3 Warehouses		
Prime Partner Name:	Arquiplan, Lda		
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Governance and Systems	OHSS	0	0
------------------------	------	---	---

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 7388	Mechanism Name: Construction of 11 Type II Rural Health Centers
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Técnicos Construtores (TEC), Lda	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	7388
Mechanism Name:	Construction of 11 Type II Rural Health Centers
Prime Partner Name:	Técnicos Construtores (TEC), Lda



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 9564	Mechanism Name: ASCP
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: American Society of Clinical Pathology	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 1,395,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,395,000	
Funding Source	Funding Amount
GHP-State	1,395,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 9564
Mechanism Name: ASCP
Prime Partner Name: American Society of Clinical Pathology



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	1,195,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	200,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 9568	Mechanism Name: ASM
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: American Society for Microbiology	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 1,460,645	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,460,645	
Funding Source	Funding Amount
GHP-State	1,460,645

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 9568			
Mechanism Name: ASM			
Prime Partner Name: American Society for Microbiology			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	471,559	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	360,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	350,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	279,086	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 9570		Mechanism Name: PAS Small Grants	
Funding Agency: State/AF		Procurement Type: Grant	
Prime Partner Name: U.S. Department of State			
Agreement Start Date: Redacted		Agreement End Date: Redacted	
TBD: No		New Mechanism: No	
G2G: No		Managing Agency:	

Total All Funding Sources: 435,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 435,000	
Funding Source	Funding Amount



GHP-State	435,000
-----------	---------

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 9570			
Mechanism Name: PAS Small Grants			
Prime Partner Name: U.S. Department of State			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	198,214	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	88,072	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	15,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	26,794	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	106,920	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
-------------------------	--------------	-------------



PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	3,016
PP_PREV_DSD	Aggregated Age/sex: <15 Male	619
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	905
PP_PREV_DSD	Aggregated Age/sex: <15 Female	889
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	603
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	775
KP_PREV_DSD	Total estimated number of key population in the catchment area	10,906
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	100
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	675
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	2,694
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	8,212
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,280
HTC_TST_DSD	Age/sex: 15-19 Male	48
HTC_TST_DSD	Age/sex: 20-24 Male	47



HTC_TST_DSD	Age/sex: 25-49 Male	85
HTC_TST_DSD	Age/sex: 50+ Male	18
HTC_TST_DSD	Age/sex: 15-19 Female	86
HTC_TST_DSD	Age/sex: 20-24 Female	127
HTC_TST_DSD	Age/sex: 25-49 Female	207
HTC_TST_DSD	Age/sex: 50+ Female	22
HTC_TST_DSD	Sum of Age/Sex disaggregates	640
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	3
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	7
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	31
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	7
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	11
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	25
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	59
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	9
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	396
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	884
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	1,280
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	1,280
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	101
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	225
HTC_TST_DSD	Service Delivery Point (Community): Other	1,280
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	1,800
OVC_SERV_DSD	Age/Sex: 18+ Male	36
OVC_SERV_DSD	Age/Sex: 18+ Female	72
OVC_SERV_DSD	Sum of Age/Sex disaggregates	108
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	828

Approved



OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	864
--------------	-----------------------------------	-----

Implementing Mechanism Details

Mechanism ID: 9725	Mechanism Name: Twinning - AIHA
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement
Prime Partner Name: American International Health Alliance Twinning Center	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 340,340	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 340,340	
Funding Source	Funding Amount
GHP-State	340,340

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	9725		
Mechanism Name:	Twinning - AIHA		
Prime Partner Name:	American International Health Alliance Twinning Center		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	340,340	0

Implementing Mechanism Indicator Information

(No data provided.)



Implementing Mechanism Details

Mechanism ID: 9811	Mechanism Name: Friends in Global Health
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Vanderbilt University	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 26,903,259	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 26,903,259	
Funding Source	Funding Amount
GHP-State	26,903,259

Cross-Cutting Budget Attribution(s)

Gender: GBV	1,328,022
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation

Budget Code Information

Mechanism ID:	9811		
Mechanism Name:	Friends in Global Health		
Prime Partner Name:	Vanderbilt University		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	2,308,629	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	424,461	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	429,671	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	1,238,280	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	2,600,158	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	17,969,195	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	1,932,865	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	132,674
PMTCT_ART_DSD	New on ART	7,527
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	5,016
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	12,632
PMTCT_ART_TA	New on ART	310
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	207
PMTCT_STAT_DSD	Number of pregnant women with known HIV status	132,674



	(includes women who were tested for HIV and received their results)	
PMTCT_STAT_DSD	Number of new ANC and L&D clients	134,014
PMTCT_STAT_DSD	By: Known positives at entry	5,065
PMTCT_STAT_DSD	By: Number of new positives identified	7,604
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	12,669
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: <15	7
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 15-19	276
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 20-24	609
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 15-19	125
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 20-24	370
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15	428
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15-19	3,687
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 20-24	4,998
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 25-49	6,694
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 50+	16
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 25-49	731
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 50+	12
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 25-49	947
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 50+	18



PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): <15	422
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 15-19	3,651
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 20-24	4,950
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 25-49	6,626
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 50+	16
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	12,632
PMTCT_STAT_TA	Number of new ANC and L&D clients	12,760
PMTCT_STAT_TA	By: Known positives at entry	209
PMTCT_STAT_TA	By: Number of new positives identified	314
PMTCT_STAT_TA	Sum of Positives Status disaggregates	523
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	7,989
PP_PREV_DSD	Aggregated Age/sex: <15 Male	5,592
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	2,397
PP_PREV_DSD	Aggregated Age/sex: <15 Female	2,397
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	1,598
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	404,213
HTC_TST_DSD	Age/sex: 10-14 Male	1,809
HTC_TST_DSD	Age/sex: 15-19 Male	1,870
HTC_TST_DSD	Age/sex: 20-24 Male	1,833
HTC_TST_DSD	Age/sex: 25-49 Male	3,291
HTC_TST_DSD	Age/sex: 50+ Male	694
HTC_TST_DSD	Age/sex: 10-14 Female	1,188
HTC_TST_DSD	Age/sex: 15-19 Female	7,130
HTC_TST_DSD	Age/sex: 20-24 Female	10,529
HTC_TST_DSD	Age/sex: 25-49 Female	17,185
HTC_TST_DSD	Age/sex: 50+ Female	1,789
HTC_TST_DSD	Sum of Age/Sex disaggregates	47,318



HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	65
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	202
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	497
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	2,202
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	469
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	108
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	805
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	1,799
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	4,299
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	633
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	33,563
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	63,089
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	41,383
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	266,239
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	74,946
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	329,328
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	404,274
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	1,740
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	14,599
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	2,004
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	29,853
HTC_TST_DSD	Test Result by Age: Positive: <1	93
HTC_TST_DSD	Test Result by Age: Positive: 1-9	396
HTC_TST_DSD	Age/sex: <1	854
HTC_TST_DSD	Age/sex: 1-9	3,449



HTC_TST_DSD	Service Delivery Point (Community): Index testing	20,417
HTC_TST_DSD	Service Delivery Point (Community): Other	5,745
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	116,513
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	5,559
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	7,952
HTC_TST_DSD	Service Delivery Point (Facility): VCT	90,653
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	128,751
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	3,023
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	25,600
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	22,543
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	879
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	2,059
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,626
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	17,979
HTC_TST_TA	Sum of Aggregated Age/Sex <15	2,505
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	20,038
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	22,543
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Male	26
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	263
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Female	33
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	806
HTC_TST_TA	Service Delivery Point (Facility): Outpatient	7,019
HTC_TST_TA	Service Delivery Point (Facility): Pediatric	134



HTC_TST_TA	Service Delivery Point (Facility): Other PITC	303
HTC_TST_TA	Service Delivery Point (Facility): VCT	2,518
HTC_TST_TA	Service Delivery Point (Facility): PMTCT	12,463
HTC_TST_TA	Service Delivery Point (Facility): TB Clinics	106
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	8,868
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	8,868
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	3,106
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	5,767
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	333
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	333
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	117
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	216
GEND_GBV_DSD	Number of people receiving post-GBV care	3,908
GEND_GBV_DSD	Age/Sex: <10 Male	13
GEND_GBV_DSD	Age/Sex: 10-14 Male	33
GEND_GBV_DSD	Age/Sex: 20-24 Male	33
GEND_GBV_DSD	Age/Sex: 25-49 Male	13
GEND_GBV_DSD	Age/Sex: <10 Female	67
GEND_GBV_DSD	Age/Sex: 10-14 Female	296
GEND_GBV_DSD	Age/Sex: 20-24 Female	296
GEND_GBV_DSD	Age/Sex: 25-49 Female	240



GEND_GBV_DSD	Sum of Age/Sex Disaggregates	409
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	2,967
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	1,012
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	742
GEND_GBV_DSD	Age/Sex: 15-19 Female	296
GEND_GBV_DSD	Age/Sex: 15-19 male	33
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	4,097
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	4,097
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1,430
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	2,669
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	75
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	75
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	26
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	49



	TB treatment during the reporting period)	
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	106,278
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	6,056
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	32,982
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	6,056
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	61,252
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	8,506
TB_SCREENDX_TA	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	3,364
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Male	191
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Male	1,045
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Female	191
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Female	1,939
TB_SCREENDX_TA	Screen Results: Screened Positive for TB	270
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	7,977
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	3,578
PMTCT_EID_DSD	Sum of Infant Age disaggregates	11,555
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	393
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	286
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	288
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	130
PMTCT_EID_TA	Sum of Infant Age disaggregates	418
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	14



PMTCT_EID_TA	Number of infants with a positive virological test result within 12 months of birth	10
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	89,366
TX_CURR_DSD	Age/Sex: 15-19 Male	669
TX_CURR_DSD	Age/Sex: 15-19 Female	991
TX_CURR_DSD	Sum of age/sex disaggregates	1,660
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	4,218
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	28,343
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	4,218
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	52,635
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	8,436
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	80,978
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	89,414
TX_CURR_DSD	Age/Sex: <1	1,220
TX_CURR_DSD	Age/Sex: <1-9	1,465
TX_CURR_DSD	Age/Sex: 10-14 Male	315
TX_CURR_DSD	Age/Sex: 10-14 Female	315
TX_CURR_DSD	Age/Sex: 20-24 Male	1,762
TX_CURR_DSD	Age/Sex: 25-49 Male	6,378
TX_CURR_DSD	Age/Sex: 50+ Male	1,465
TX_CURR_DSD	Age/Sex: 20-24 Female	2,271
TX_CURR_DSD	Age/Sex: 25-49 Female	5,172
TX_CURR_DSD	Age/Sex: 50+ Female	823
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	2,620
TX_CURR_TA	Aggregated Age/Sex: <15 Male	126
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	829
TX_CURR_TA	Aggregated Age/Sex: <15 Female	126
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	1,539
TX_CURR_TA	Sum of Aggregated Age/Sex <15	252
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	2,368



TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	2,620
TX_CURR_TA	Age/Sex: <1	66
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	39,819
TX_NEW_DSD	By Age/Sex: <1	1,220
TX_NEW_DSD	By Age/Sex: 1-9	947
TX_NEW_DSD	By Age/Sex: 10-14 Male	97
TX_NEW_DSD	By Age/Sex: 15-19 Male	276
TX_NEW_DSD	By Age/Sex: 20-24 Male	727
TX_NEW_DSD	By Age/Sex: 25-49 Male	2,635
TX_NEW_DSD	By Age/Sex: 50+ Male	606
TX_NEW_DSD	By Age/Sex: 10-14 Female	200
TX_NEW_DSD	By Age/Sex: 15-19 Female	410
TX_NEW_DSD	By Age/Sex: 20-24 Female	938
TX_NEW_DSD	By Age/Sex: 25-49 Female	2,137
TX_NEW_DSD	By Age/Sex: 50+ Female	341
TX_NEW_DSD	Sum of Age/Sex disaggregates	8,367
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	22,987
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	12,370
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	2,256
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	2,256
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	39,869
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	798
TX_NEW_TA	Aggregated Grouping by Age: <1	66
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	475
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	257
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	34
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	34
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	800
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml)	29,495



	documented in the medical records and /or supporting laboratory results within the past 12 months.	
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	39,329
TX_PVLS_DSD	Numerator: Indication: Routine	2,750
TX_PVLS_DSD	Numerator: Indication: Targeted	26,745
TX_PVLS_DSD	Denominator: Indication: Routine	3,667
TX_PVLS_DSD	Denominator: Indication: Targeted	35,662
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	16,586
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	8,929
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	2,017
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	2,017
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	2,675
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	11,914
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	2,675
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	22,118
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	1,365
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	1,820
TX_PVLS_TA	Numerator: Indication: Targeted	1,365
TX_PVLS_TA	Denominator: Indication: Targeted	1,820
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Male	791
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Male	425
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Female	76
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Female	76
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Male	99
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Male	568
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Female	99



TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Female	1,055
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	38,382
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	50,589
TX_RET_DSD	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	102
TX_RET_DSD	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	394
TX_RET_DSD	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	52
TX_RET_DSD	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	143
TX_RET_DSD	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	373
TX_RET_DSD	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,349
TX_RET_DSD	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	309
TX_RET_DSD	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	105
TX_RET_DSD	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	455
TX_RET_DSD	Age/Sex: 20-24 Female (Numerator: Number of adults	1,044



	and children who are still alive and on treatment at 12 months after initiating ART	
TX_RET_DSD	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,378
TX_RET_DSD	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	378
TX_RET_DSD	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	226
TX_RET_DSD	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	869
TX_RET_DSD	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	115
TX_RET_DSD	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	312
TX_RET_DSD	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	820
TX_RET_DSD	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months	2,973



	prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	683
TX_RET_DSD	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	229
TX_RET_DSD	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,004
TX_RET_DSD	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,298
TX_RET_DSD	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	5,236
TX_RET_DSD	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	834
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	23,487



TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	12,645
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,151
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,151
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	30,958
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	16,674
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,507
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,507
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	711
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	1,016



TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	387
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	207
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	60
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	60
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	549
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	297
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	86
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	86

Implementing Mechanism Details

Mechanism ID: 9818	Mechanism Name: APHL
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement



Prime Partner Name: Association of Public Health Laboratories	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 1,581,183	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,581,183	
Funding Source	Funding Amount
GHP-State	1,581,183

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	9818		
Mechanism Name:	APHL		
Prime Partner Name:	Association of Public Health Laboratories		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	680,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	420,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	481,183	0



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 9856	Mechanism Name: MISAU BS
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ministry of Health, Mozambique	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 200,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 200,000	
Funding Source	Funding Amount
GHP-State	200,000

Cross-Cutting Budget Attribution(s)

Gender: GBV	75,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building



Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research

Budget Code Information

Mechanism ID:	9856		
Mechanism Name:	MISAU BS		
Prime Partner Name:	Ministry of Health, Mozambique		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMBL	200,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 10971	Mechanism Name: FADM, Department of Defense Support
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: U.S. Department of Defense (Defense)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0



Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 10971			
Mechanism Name: FADM, Department of Defense Support			
Prime Partner Name: U.S. Department of Defense (Defense)			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 11463	Mechanism Name: United States Peace Corps/ Mozambique
Funding Agency: PC	Procurement Type: USG Core
Prime Partner Name: U.S. Peace Corps	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 112,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 112,000	
Funding Source	Funding Amount
GHP-State	112,000



Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	11463		
Mechanism Name:	United States Peace Corps/ Mozambique		
Prime Partner Name:	U.S. Peace Corps		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	112,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	13,810
PP_PREV_DSD	Aggregated Age/sex: <15 Male	2,834
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	4,145
PP_PREV_DSD	Aggregated Age/sex: <15 Female	4,073
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	2,762

Implementing Mechanism Details

Mechanism ID: 11580	Mechanism Name: Johns Hopkins
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: JHPIEGO	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 22,674,145	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 22,674,145	
Funding Source	Funding Amount
GHP-State	22,674,145

Cross-Cutting Budget Attribution(s)

Human Resources for Health	2,748,513
Motor Vehicles: Purchased	600,000
Gender: GBV	424,480
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Condom programming	348,754

Budget Code Information

Mechanism ID: 11580 Mechanism Name: Johns Hopkins Prime Partner Name: JHPIEGO			
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HBHC	192,471	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	673,656	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	1,320,164	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	14,433,828	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	1,607,657	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	350,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	3,696,369	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	400,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	247,804



VMMC_CIRC_DSD	By Age: 10-14	74,876
VMMC_CIRC_DSD	By Age: 15-19	69,171
VMMC_CIRC_DSD	By Age: 20-24	57,639
VMMC_CIRC_DSD	By Age: 25-29	34,589
VMMC_CIRC_DSD	By Age: 30-49	11,529
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	201,686
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	247,804
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	247,804
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	316,424
HTC_TST_DSD	Age/sex: 10-14 Male	3,753
HTC_TST_DSD	Age/sex: 15-19 Male	4,952
HTC_TST_DSD	Age/sex: 20-24 Male	4,857
HTC_TST_DSD	Age/sex: 25-49 Male	8,716
HTC_TST_DSD	Age/sex: 50+ Male	1,835
HTC_TST_DSD	Sum of Age/Sex disaggregates	24,113
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	2
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	21
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	50
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	224
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	48
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	83,777
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	202,631
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	21,822
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	8,411
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	105,599
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	211,042
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	316,641



HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	2,139
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	9,952
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	2,043
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	3,422
HTC_TST_DSD	Test Result by Age: Positive: 1-9	7
HTC_TST_DSD	Age/sex: <1	766
HTC_TST_DSD	Age/sex: 1-9	3,087
HTC_TST_DSD	Service Delivery Point (Community): Index testing	68,620
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	247,804
GEND_GBV_DSD	Number of people receiving post-GBV care	2,027
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	1,522
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	507
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	380

Implementing Mechanism Details

Mechanism ID: 12149	Mechanism Name: SCIP Zambezia
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: World Vision International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 1,125,165	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,125,165	
Funding Source	Funding Amount
GHP-State	1,125,165



Cross-Cutting Budget Attribution(s)

Economic Strengthening	389,324
Gender: GBV	100,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Gender: Gender Equality	200,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Focus Area:	Equity in HIV prevention, care, treatment and support
Water	50,000

Budget Code Information

Mechanism ID: 12149			
Mechanism Name: SCIP Zambezia			
Prime Partner Name: World Vision International			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	960,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	165,165	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
------------------	-------	------



PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	2,847
PP_PREV_DSD	Aggregated Age/sex: <15 Male	1,993
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	854
PP_PREV_DSD	Aggregated Age/sex: <15 Female	854
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	569
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	16,870
HTC_TST_DSD	Age/sex: 15-19 Female	554
HTC_TST_DSD	Age/sex: 20-24 Female	818
HTC_TST_DSD	Age/sex: 25-49 Female	1,336
HTC_TST_DSD	Age/sex: 50+ Female	139
HTC_TST_DSD	Sum of Age/Sex disaggregates	2,847
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	23
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	52
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	124
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	18
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	4,459
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	3,427
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	4,459
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	4,565
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	8,918
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	7,992
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	16,910
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	173
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+	577



	Male	
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	173
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	505
HTC_TST_DSD	Service Delivery Point (Community): Index testing	14,023
HTC_TST_DSD	Service Delivery Point (Community): Other	2,847

Implementing Mechanism Details

Mechanism ID: 12150	Mechanism Name: Systems for Improved Access to Pharmaceuticals and Services (SIAPS)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Management Sciences for Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	12150
----------------------	--------------



Mechanism Name:	Systems for Improved Access to Pharmaceuticals and Services (SIAPS)		
Prime Partner Name:	Management Sciences for Health		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 12159	Mechanism Name: Strengthening HIV and GBV Prevention within the Police
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: United Nations Development Programme	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information



Mechanism ID: 12159			
Mechanism Name: Strengthening HIV and GBV Prevention within the Police			
Prime Partner Name: United Nations Development Programme			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 12165	Mechanism Name: Strategic Information Improvement in Mozambique (SIIM) Project
Funding Agency: USAID	Procurement Type: Grant
Prime Partner Name: Health Alliance International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 980,526	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 980,526	
Funding Source	Funding Amount
GHP-State	980,526

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information



Mechanism ID:	12165		
Mechanism Name:	Strategic Information Improvement in Mozambique (SIIM) Project		
Prime Partner Name:	Health Alliance International		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	500,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	480,526	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 12168	Mechanism Name: Increasing access to HIV prevention care and treatment for Key Populations in Mozambique
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Pathfinder International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 2,787,884	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 2,787,884	
Funding Source	Funding Amount
GHP-State	2,787,884

Cross-Cutting Budget Attribution(s)

Motor Vehicles: Purchased	163,224
Key Populations: MSM and TG	427,459



Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Focus Area:	Monitoring and evaluation of MSM/TG programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for MSM/TG
Key Populations: FSW	1,500,788
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Focus Area:	Monitoring and evaluation of SW programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for SWs
Gender: GBV	100,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Implementation



Human Resources for Health	96,715
----------------------------	--------

Budget Code Information

Mechanism ID:	12168		
Mechanism Name:	Increasing access to HIV prevention care and treatment for Key Populations in Mozambique		
Prime Partner Name:	Pathfinder International		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	144,355	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	66,319	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	346,064	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	2,131,146	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions	26,115



	that are based on evidence and/or meet the minimum standards required	
KP_PREV_DSD	Total estimated number of key population in the catchment area	41,567
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	3,653
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	11,455
KP_PREV_DSD	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	11,007
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	7,538
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	22,892
KP_PREV_DSD	By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)	11,137
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	20,906
HTC_TST_DSD	Age/sex: 15-19 Male	452
HTC_TST_DSD	Age/sex: 20-24 Male	443
HTC_TST_DSD	Age/sex: 25-49 Male	795



HTC_TST_DSD	Age/sex: 50+ Male	167
HTC_TST_DSD	Age/sex: 15-19 Female	66
HTC_TST_DSD	Age/sex: 20-24 Female	99
HTC_TST_DSD	Age/sex: 25-49 Female	161
HTC_TST_DSD	Age/sex: 50+ Female	17
HTC_TST_DSD	Sum of Age/Sex disaggregates	2,200
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	13
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	32
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	140
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	30
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	4
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	10
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	22
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	4
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	11,202
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	9,325
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	20,527
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	20,527
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	1,346
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	867
HTC_TST_DSD	Service Delivery Point (Community): Other	20,906

Implementing Mechanism Details

Mechanism ID: 12619	Mechanism Name: AABB
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: American Association of Blood Banks	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Approved



Total All Funding Sources: 490,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 490,000	
Funding Source	Funding Amount
GHP-State	490,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 12619			
Mechanism Name: AABB			
Prime Partner Name: American Association of Blood Banks			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMBL	490,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 12648	Mechanism Name: Promoting the Quality of Medicines (PQM)
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: United States Pharmacopeia	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:



Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	12648		
Mechanism Name:	Promoting the Quality of Medicines (PQM)		
Prime Partner Name:	United States Pharmacopeia		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 12665	Mechanism Name: DPS Cabo Delgado Province
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Provincial Directorate of Health, Cabo Delgado	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC



Total All Funding Sources: 388,710	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 388,710	
Funding Source	Funding Amount
GHP-State	388,710

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 12665			
Mechanism Name: DPS Cabo Delgado Province			
Prime Partner Name: Provincial Directorate of Health, Cabo Delgado			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	144,355	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	144,355	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 12681	Mechanism Name: JEMBI
----------------------------	------------------------------



Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: JEMBI	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 875,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 875,000	
Funding Source	Funding Amount
GHP-State	875,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 12681 Mechanism Name: JEMBI Prime Partner Name: JEMBI			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	875,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 12702	Mechanism Name: UCSF
----------------------------	-----------------------------



Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of California at San Francisco	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 5,130,913	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 5,130,913	
Funding Source	Funding Amount
GHP-State	5,130,913

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 12702			
Mechanism Name: UCSF			
Prime Partner Name: University of California at San Francisco			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	150,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	1,000,000	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	450,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	925,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	2,405,913	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 12998	Mechanism Name: DPS Maputo Province
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Provincial Directorate of Health, Maputo	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 213,226	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 213,226	
Funding Source	Funding Amount
GHP-State	213,226



Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	12998		
Mechanism Name:	DPS Maputo Province		
Prime Partner Name:	Provincial Directorate of Health, Maputo		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	86,613	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	40,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	86,613	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13022	Mechanism Name: Clinical Services System Strengthening (CHASS)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No



G2G: No	Managing Agency:
---------	------------------

Total All Funding Sources: 33,510,895	
Applied Pipeline Amount: 4,300,000	
Total All Funding Sources and Applied Pipeline Amount: 37,810,895	
Funding Source	Funding Amount
GHP-State	33,510,895

Cross-Cutting Budget Attribution(s)

Human Resources for Health	324,029
Economic Strengthening	589,405
Gender: Gender Equality	8,236,197
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Focus Area:	Equity in HIV prevention, care, treatment and support

Budget Code Information

Mechanism ID:	13022		
Mechanism Name:	Clinical Services System Strengthening (CHASS)		
Prime Partner Name:	FHI 360		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	4,276,878	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	1,067,171	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	300,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	250,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	3,808,231	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	1,500,168	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	22,308,447	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	241,142
PMTCT_ART_DSD	New on ART	14,647
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	9,761
PMTCT_ART_TA	Number of pregnant women with known HIV status	100,332



	(includes women who were tested for HIV and received their results)	
PMTCT_ART_TA	New on ART	2,550
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	1,706
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	241,142
PMTCT_STAT_DSD	Number of new ANC and L&D clients	243,577
PMTCT_STAT_DSD	By: Known positives at entry	9,862
PMTCT_STAT_DSD	By: Number of new positives identified	14,793
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	24,655
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: <15	10
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 15-19	472
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 20-24	1,044
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 15-19	211
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 20-24	635
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15	658
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15-19	5,685
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 20-24	7,710
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 25-49	10,321
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 50+	24
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 25-49	1,251
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of	21



	known positives: 50+	
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 25-49	1,620
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 50+	30
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): <15	653
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 15-19	5,628
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 20-24	7,632
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 25-49	10,216
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 50+	24
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	100,332
PMTCT_STAT_TA	Number of new ANC and L&D clients	101,346
PMTCT_STAT_TA	By: Known positives at entry	1,718
PMTCT_STAT_TA	By: Number of new positives identified	2,577
PMTCT_STAT_TA	Sum of Positives Status disaggregates	4,295
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	8,159
PP_PREV_DSD	Aggregated Age/sex: <15 Male	5,711
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	2,448
PP_PREV_DSD	Aggregated Age/sex: <15 Female	2,448
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	1,632
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,179,444
HTC_TST_DSD	Age/sex: 10-14 Male	4,571
HTC_TST_DSD	Age/sex: 15-19 Male	1,955
HTC_TST_DSD	Age/sex: 20-24 Male	1,918
HTC_TST_DSD	Age/sex: 25-49 Male	3,441
HTC_TST_DSD	Age/sex: 50+ Male	726
HTC_TST_DSD	Age/sex: 10-14 Female	2,446



HTC_TST_DSD	Age/sex: 15-19 Female	8,185
HTC_TST_DSD	Age/sex: 20-24 Female	12,087
HTC_TST_DSD	Age/sex: 25-49 Female	19,728
HTC_TST_DSD	Age/sex: 50+ Female	2,058
HTC_TST_DSD	Sum of Age/Sex disaggregates	57,115
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	166
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	185
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	458
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	2,028
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	433
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	241
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	718
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	1,610
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	3,846
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	567
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	111,922
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	187,825
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	132,498
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	747,405
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	244,420
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	935,230
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	1,179,650
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	4,918
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	34,481
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	5,736
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+	66,663



	Female	
HTC_TST_DSD	Test Result by Age: Positive: <1	219
HTC_TST_DSD	Test Result by Age: Positive: 1-9	950
HTC_TST_DSD	Age/sex: <1	1,933
HTC_TST_DSD	Age/sex: 1-9	7,806
HTC_TST_DSD	Service Delivery Point (Community): Index testing	67,507
HTC_TST_DSD	Service Delivery Point (Community): Other	7,847
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	545,830
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	13,157
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	54,626
HTC_TST_DSD	Service Delivery Point (Facility): VCT	184,773
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	232,308
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	5,893
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	67,503
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	337,740
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	21,400
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	41,666
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	30,476
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	244,198
HTC_TST_TA	Sum of Aggregated Age/Sex <15	51,876
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	285,864
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	337,740
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Male	589
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	4,917
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15	760



	Female	
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	11,517
HTC_TST_TA	Service Delivery Point (Facility): Outpatient	169,519
HTC_TST_TA	Service Delivery Point (Facility): Pediatric	6,042
HTC_TST_TA	Service Delivery Point (Facility): Other PITC	22,996
HTC_TST_TA	Service Delivery Point (Facility): VCT	38,392
HTC_TST_TA	Service Delivery Point (Facility): PMTCT	98,654
HTC_TST_TA	Service Delivery Point (Facility): TB Clinics	2,137
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	20,672
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	20,672
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	7,239
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	13,441
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	6,146
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	6,146
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2,150
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	3,997
GEND_GBV_DSD	Number of people receiving post-GBV care	8,946
GEND_GBV_DSD	Age/Sex: <10 Male	24
GEND_GBV_DSD	Age/Sex: 10-14 Male	61
GEND_GBV_DSD	Age/Sex: 20-24 Male	61
GEND_GBV_DSD	Age/Sex: 25-49 Male	24



GEND_GBV_DSD	Age/Sex: <10 Female	120
GEND_GBV_DSD	Age/Sex: 10-14 Female	545
GEND_GBV_DSD	Age/Sex: 20-24 Female	545
GEND_GBV_DSD	Age/Sex: 25-49 Female	435
GEND_GBV_DSD	Sum of Age/Sex Disaggregates	750
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	6,729
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	2,260
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	1,686
GEND_GBV_DSD	Age/Sex: 15-19 Female	545
GEND_GBV_DSD	Age/Sex: 15-19 male	61
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	10,664
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	10,664
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	3,730
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	6,937
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	2,308
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	2,308
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with	809

	documented HIV-positive status who are on ART during TB treatment during the reporting period)	
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1,501
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	256,037
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	16,315
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	78,217
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	16,315
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	145,269
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	20,484
TB_SCREENDX_TA	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	48,678
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Male	1,829
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Male	15,766
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Female	1,829
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Female	29,281
TB_SCREENDX_TA	Screen Results: Screened Positive for TB	3,895
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	15,683
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	7,045
PMTCT_EID_DSD	Sum of Infant Age disaggregates	22,728
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	785
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	571
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	2,327
PMTCT_EID_TA	By infants who received their first virologic HIV test	1,045



	between 2 and 12 months of age	
PMTCT_EID_TA	Sum of Infant Age disaggregates	3,372
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	115
PMTCT_EID_TA	Number of infants with a positive virological test result within 12 months of birth	84
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	238,233
TX_CURR_DSD	Age/Sex: 15-19 Male	1,145
TX_CURR_DSD	Age/Sex: 15-19 Female	1,693
TX_CURR_DSD	Sum of age/sex disaggregates	2,838
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	10,187
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	76,280
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	10,187
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	141,656
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	20,374
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	217,936
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	238,310
TX_CURR_DSD	Age/Sex: <1	1,005
TX_CURR_DSD	Age/Sex: <1-9	2,534
TX_CURR_DSD	Age/Sex: 10-14 Male	544
TX_CURR_DSD	Age/Sex: 10-14 Female	544
TX_CURR_DSD	Age/Sex: 20-24 Male	3,010
TX_CURR_DSD	Age/Sex: 25-49 Male	10,896
TX_CURR_DSD	Age/Sex: 50+ Male	2,500
TX_CURR_DSD	Age/Sex: 20-24 Female	3,878
TX_CURR_DSD	Age/Sex: 25-49 Female	8,834
TX_CURR_DSD	Age/Sex: 50+ Female	1,406
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	38,518
TX_CURR_TA	Aggregated Age/Sex: <15 Male	1,867
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	12,183



TX_CURR_TA	Aggregated Age/Sex: <15 Female	1,867
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	22,627
TX_CURR_TA	Sum of Aggregated Age/Sex <15	3,734
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	34,810
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	38,544
TX_CURR_TA	Age/Sex: <1	174
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	79,277
TX_NEW_DSD	By Age/Sex: <1	1,005
TX_NEW_DSD	By Age/Sex: 1-9	1,224
TX_NEW_DSD	By Age/Sex: 10-14 Male	127
TX_NEW_DSD	By Age/Sex: 15-19 Male	328
TX_NEW_DSD	By Age/Sex: 20-24 Male	863
TX_NEW_DSD	By Age/Sex: 25-49 Male	3,124
TX_NEW_DSD	By Age/Sex: 50+ Male	717
TX_NEW_DSD	By Age/Sex: 10-14 Female	258
TX_NEW_DSD	By Age/Sex: 15-19 Female	485
TX_NEW_DSD	By Age/Sex: 20-24 Female	1,112
TX_NEW_DSD	By Age/Sex: 25-49 Female	2,531
TX_NEW_DSD	By Age/Sex: 50+ Female	404
TX_NEW_DSD	Sum of Age/Sex disaggregates	9,949
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	45,776
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	24,655
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	4,452
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	4,452
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	79,335
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	10,805
TX_NEW_TA	Aggregated Grouping by Age: <1	174
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	6,160
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	3,317
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	673



TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	673
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	10,823
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	57,821
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	77,101
TX_PVLS_DSD	Numerator: Indication: Routine	11,368
TX_PVLS_DSD	Numerator: Indication: Targeted	46,453
TX_PVLS_DSD	Denominator: Indication: Routine	15,159
TX_PVLS_DSD	Denominator: Indication: Targeted	61,942
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	31,774
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	17,119
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	4,502
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	4,502
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	6,001
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	22,820
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	6,001
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	42,375
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	9,489
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	12,656
TX_PVLS_TA	Numerator: Indication: Routine	1,767
TX_PVLS_TA	Numerator: Indication: Targeted	7,722
TX_PVLS_TA	Denominator: Indication: Routine	2,354
TX_PVLS_TA	Denominator: Indication: Targeted	10,302
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Male	5,129



TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Male	2,767
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Female	808
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Female	808
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Male	1,074
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Male	3,685
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Female	1,074
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Female	6,844
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	43,422
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	56,598
TX_RET_DSD	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	90
TX_RET_DSD	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	344
TX_RET_DSD	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	44
TX_RET_DSD	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	125
TX_RET_DSD	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	325
TX_RET_DSD	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,177
TX_RET_DSD	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	271



TX_RET_DSD	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	90
TX_RET_DSD	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	398
TX_RET_DSD	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	910
TX_RET_DSD	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,073
TX_RET_DSD	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	331
TX_RET_DSD	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	58
TX_RET_DSD	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	220
TX_RET_DSD	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	30
TX_RET_DSD	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	79



TX_RET_DSD	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	209
TX_RET_DSD	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	755
TX_RET_DSD	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	175
TX_RET_DSD	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	58
TX_RET_DSD	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	256
TX_RET_DSD	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	586
TX_RET_DSD	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,332
TX_RET_DSD	Age/Sex: 50+ Female (Denominator: Total number of	212



	adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	25,333
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	13,649
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,265
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,265
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	33,046
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	17,786
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,924
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	2,924



	stopped ART, and those lost to follow-up)	
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	7,633
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	10,901
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,378
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,356
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	462
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	462
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6,250
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,364
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	657
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total	657



	number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	208
HRH_PRE	By Graduates: Nurses	104
HRH_PRE	By Graduates: Other	104
HRH_PRE	Sum of Graduates disaggreagtes	208

Implementing Mechanism Details

Mechanism ID: 13160	Mechanism Name: DPS Zambezia Province
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Provincial Directorate of Health, Zambezia	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 677,419	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 677,419	
Funding Source	Funding Amount
GHP-State	677,419

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information



Mechanism ID: 13160			
Mechanism Name: DPS Zambezia Province			
Prime Partner Name: Provincial Directorate of Health, Zambezia			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	288,710	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	288,709	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13313	Mechanism Name: National Public Health Reference Laboratory
Funding Agency: State/AF	Procurement Type: USG Core
Prime Partner Name: Regional Procurement Support Office/Frankfurt	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 1,184,003	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,184,003	
Funding Source	Funding Amount
GHP-State	1,184,003



Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 13313			
Mechanism Name: National Public Health Reference Laboratory			
Prime Partner Name: Regional Procurement Support Office/Frankfurt			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	1,184,003	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13583		Mechanism Name: ICAP	
Funding Agency: HHS/CDC		Procurement Type: Cooperative Agreement	
Prime Partner Name: Columbia University Mailman School of Public Health			
Agreement Start Date: Redacted		Agreement End Date: Redacted	
TBD: No		New Mechanism: No	
G2G: No		Managing Agency:	

Total All Funding Sources: 18,640,588	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 18,640,588	
Funding Source	Funding Amount
GHP-State	18,640,588



Cross-Cutting Budget Attribution(s)

Gender: GBV	524,226
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation

Budget Code Information

Mechanism ID: 13583			
Mechanism Name: ICAP			
Prime Partner Name: Columbia University Mailman School of Public Health			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	2,204,541	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	498,079	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	395,311	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	3,333,881	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	1,216,110	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	2,555,292	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Treatment	HTXS	6,737,127	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	1,700,247	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	230,490
PMTCT_ART_DSD	New on ART	7,304
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	4,870
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	128,073
PMTCT_ART_TA	New on ART	2,213
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	1,479
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	230,490
PMTCT_STAT_DSD	Number of new ANC and L&D clients	232,821
PMTCT_STAT_DSD	By: Known positives at entry	4,917
PMTCT_STAT_DSD	By: Number of new positives identified	7,380
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	12,297
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	128,073
PMTCT_STAT_TA	Number of new ANC and L&D clients	129,370
PMTCT_STAT_TA	By: Known positives at entry	1,492
PMTCT_STAT_TA	By: Number of new positives identified	2,237
PMTCT_STAT_TA	Sum of Positives Status disaggregates	3,729



VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	55,030
VMMC_CIRC_DSD	By Age: 10-14	13,758
VMMC_CIRC_DSD	By Age: 15-19	16,509
VMMC_CIRC_DSD	By Age: 20-24	13,758
VMMC_CIRC_DSD	By Age: 25-29	8,255
VMMC_CIRC_DSD	By Age: 30-49	2,750
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	44,025
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	55,030
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	55,030
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	550,027
HTC_TST_DSD	Age/sex: 10-14 Male	1,755
HTC_TST_DSD	Age/sex: 15-19 Male	2,317
HTC_TST_DSD	Age/sex: 20-24 Male	2,272
HTC_TST_DSD	Age/sex: 25-49 Male	4,077
HTC_TST_DSD	Age/sex: 50+ Male	858
HTC_TST_DSD	Sum of Age/Sex disaggregates	11,279
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	1
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	9
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	24
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	104
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	21
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	43,812
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	96,218
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	42,920
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	367,102



HTC_TST_DSD	Sum of Aggregated Age/Sex <15	86,732
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	463,320
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	550,052
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	1,343
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	12,860
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	1,654
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	28,441
HTC_TST_DSD	Test Result by Age: Positive: 1-9	4
HTC_TST_DSD	Age/sex: <1	358
HTC_TST_DSD	Age/sex: 1-9	1,444
HTC_TST_DSD	Service Delivery Point (Community): Index testing	7,615
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	150,729
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	1,289
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	18,175
HTC_TST_DSD	Service Delivery Point (Facility): VCT	57,196
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	55,030
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	227,124
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	3,560
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	29,309
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	248,285
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	10,083
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	23,325
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	18,150
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION	196,727



	ONLY: 15+ Female	
HTC_TST_TA	Sum of Aggregated Age/Sex <15	28,233
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	220,052
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	248,285
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Male	266
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	2,609
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Female	357
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	7,289
HTC_TST_TA	Service Delivery Point (Facility): Outpatient	89,444
HTC_TST_TA	Service Delivery Point (Facility): Pediatric	396
HTC_TST_TA	Service Delivery Point (Facility): Other PITC	6,527
HTC_TST_TA	Service Delivery Point (Facility): VCT	23,172
HTC_TST_TA	Service Delivery Point (Facility): PMTCT	127,016
HTC_TST_TA	Service Delivery Point (Facility): TB Clinics	1,730
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	9,630
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	9,630
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	3,374
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	6,257
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	4,341
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	4,341
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with	1,520



	documented HIV status, during the reporting period)	
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2,822
GEND_GBV_DSD	Number of people receiving post-GBV care	1,279
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	966
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	329
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	244
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	3,892
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	3,892
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1,365
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	2,529
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,184
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	1,184
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	415
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The	772



	number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	119,083
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	5,122
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	38,128
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	5,122
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	70,803
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	9,525
TB_SCREENDX_TA	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	32,208
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Male	1,478
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Male	10,243
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Female	1,478
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Female	19,026
TB_SCREENDX_TA	Screen Results: Screened Positive for TB	2,574
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	7,711
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	3,463
PMTCT_EID_DSD	Sum of Infant Age disaggregates	11,174
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	382
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	278
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	2,059
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	925
PMTCT_EID_TA	Sum of Infant Age disaggregates	2,984

PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	103
PMTCT_EID_TA	Number of infants with a positive virological test result within 12 months of birth	76
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	101,130
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	4,620
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	32,190
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	4,620
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	59,768
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	9,240
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	91,958
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	101,198
TX_CURR_DSD	Age/Sex: <1	604
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	25,642
TX_CURR_TA	Aggregated Age/Sex: <15 Male	1,263
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	8,095
TX_CURR_TA	Aggregated Age/Sex: <15 Female	1,263
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	15,039
TX_CURR_TA	Sum of Aggregated Age/Sex <15	2,526
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	23,134
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	25,660
TX_CURR_TA	Age/Sex: <1	136
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	37,251
TX_NEW_DSD	By Age/Sex: <1	604
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	21,173
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	11,386
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	2,375
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	2,375
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	37,309



TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	5,912
TX_NEW_TA	Aggregated Grouping by Age: <1	136
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	3,236
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	1,742
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	474
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	474
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	5,926
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	25,067
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	33,419
TX_PVLS_DSD	Numerator: Indication: Routine	4,861
TX_PVLS_DSD	Numerator: Indication: Targeted	20,206
TX_PVLS_DSD	Denominator: Indication: Routine	6,480
TX_PVLS_DSD	Denominator: Indication: Targeted	26,939
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	13,714
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	7,386
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	2,016
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	2,016
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	2,679
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	9,841
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	2,679
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	18,281
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	7,994
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record	10,662



	and /or laboratory records in the past 12 months.	
TX_PVLS_TA	Numerator: Indication: Routine	944
TX_PVLS_TA	Numerator: Indication: Targeted	7,050
TX_PVLS_TA	Denominator: Indication: Routine	1,254
TX_PVLS_TA	Denominator: Indication: Targeted	9,408
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Male	4,456
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Male	2,396
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Female	579
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Female	579
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Male	771
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Male	3,200
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Female	771
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Female	5,943
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	35,365
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	46,475
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	21,428
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	11,537
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,234
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,234
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	28,164



	including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	15,164
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,610
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,610
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	7,504
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	10,725
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,258
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,293
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	483
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	483



TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6,085
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,275
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	688
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	688
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	70
HRH_PRE	By Graduates: Nurses	70
HRH_PRE	Sum of Graduates disaggreagtes	70

Implementing Mechanism Details

Mechanism ID: 13654	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 13661	TBD: Yes
---------------------	----------



REDACTED

Implementing Mechanism Details

Mechanism ID: 13668	Mechanism Name: ARIEL
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Fundacao ARIEL Contra a SIDA Pediatrica	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 17,161,676	
Applied Pipeline Amount: 5,500,000	
Total All Funding Sources and Applied Pipeline Amount: 22,661,676	
Funding Source	Funding Amount
GHP-State	17,161,676

Cross-Cutting Budget Attribution(s)

Human Resources for Health	773,720
Gender: GBV	853,849
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation

Budget Code Information

Mechanism ID: 13668			
Mechanism Name: ARIEL			
Prime Partner Name: Fundacao ARIEL Contra a SIDA Pediatrica			
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HBHC	1,335,298	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	153,633	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	362,814	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	2,125,709	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	1,699,042	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	10,492,973	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	992,207	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	130,221
PMTCT_ART_DSD	New on ART	9,831
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	6,550



PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	23,004
PMTCT_ART_TA	New on ART	489
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	325
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	130,221
PMTCT_STAT_DSD	Number of new ANC and L&D clients	131,534
PMTCT_STAT_DSD	By: Known positives at entry	6,619
PMTCT_STAT_DSD	By: Number of new positives identified	9,926
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	16,545
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	23,004
PMTCT_STAT_TA	Number of new ANC and L&D clients	23,235
PMTCT_STAT_TA	By: Known positives at entry	330
PMTCT_STAT_TA	By: Number of new positives identified	494
PMTCT_STAT_TA	Sum of Positives Status disaggregates	824
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	749,406
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	75,575
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	118,252
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	86,768
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	468,861
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	162,343
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	587,113
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	749,456



HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	3,409
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	23,028
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	4,005
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	43,611
HTC_TST_DSD	Service Delivery Point (Community): Index testing	16,075
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	442,724
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	10,790
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	16,272
HTC_TST_DSD	Service Delivery Point (Facility): VCT	81,486
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	122,560
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	2,152
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	57,347
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	70,873
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	4,028
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	9,770
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	5,876
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	51,199
HTC_TST_TA	Sum of Aggregated Age/Sex <15	9,904
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	60,969
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	70,873
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Male	54
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+	561



	Male	
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Female	71
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	1,574
HTC_TST_TA	Service Delivery Point (Facility): Outpatient	34,877
HTC_TST_TA	Service Delivery Point (Facility): Pediatric	102
HTC_TST_TA	Service Delivery Point (Facility): Other PITC	1,178
HTC_TST_TA	Service Delivery Point (Facility): VCT	11,771
HTC_TST_TA	Service Delivery Point (Facility): PMTCT	22,790
HTC_TST_TA	Service Delivery Point (Facility): TB Clinics	155
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	12,102
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	12,102
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	4,233
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	7,872
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	993
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	993
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	349
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	645
GEND_GBV_DSD	Number of people receiving post-GBV care	1,397
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	1,055



GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	359
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	262
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	7,416
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	7,416
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	2,597
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	4,821
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	347
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	347
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	121
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	226
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	178,152
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	7,518



TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	57,118
TB_SCREENDX_DSD	Screened for TB by Age/Sex: <15 Female	7,518
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	106,077
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	14,251
TB_SCREENDX_TA	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	6,327
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Male	292
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Male	2,012
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Female	292
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Female	3,738
TB_SCREENDX_TA	Screen Results: Screened Positive for TB	505
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	10,465
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	4,708
PMTCT_EID_DSD	Sum of Infant Age disaggregates	15,173
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	523
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	378
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	454
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	204
PMTCT_EID_TA	Sum of Infant Age disaggregates	658
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	22
PMTCT_EID_TA	Number of infants with a positive virological test result within 12 months of birth	16
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	160,167
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	6,615



TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	51,462
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	6,615
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	95,546
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	13,230
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	147,008
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	160,238
TX_CURR_DSD	Age/Sex: <1	662
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	4,993
TX_CURR_TA	Aggregated Age/Sex: <15 Male	256
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	1,569
TX_CURR_TA	Aggregated Age/Sex: <15 Female	256
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	2,917
TX_CURR_TA	Sum of Aggregated Age/Sex <15	512
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	4,486
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	4,998
TX_CURR_TA	Age/Sex: <1	50
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	65,546
TX_NEW_DSD	By Age/Sex: <1	662
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	38,248
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	20,580
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	3,393
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	3,393
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	65,614
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,229
TX_NEW_TA	Aggregated Grouping by Age: <1	50
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	672
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	364
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	101
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	101



TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	1,238
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	39,188
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	52,256
TX_PVLS_DSD	Numerator: Indication: Routine	5,452
TX_PVLS_DSD	Numerator: Indication: Targeted	33,737
TX_PVLS_DSD	Denominator: Indication: Routine	7,262
TX_PVLS_DSD	Denominator: Indication: Targeted	44,994
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	21,728
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	11,703
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	2,918
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	2,918
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	3,877
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	15,604
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	3,877
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	28,977
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	1,065
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	1,422
TX_PVLS_TA	Numerator: Indication: Routine	297
TX_PVLS_TA	Numerator: Indication: Targeted	768
TX_PVLS_TA	Denominator: Indication: Routine	396
TX_PVLS_TA	Denominator: Indication: Targeted	1,026
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Male	565
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Male	303



TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Female	102
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Female	102
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Male	136
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Male	405
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Female	136
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Female	754
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	59,901
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	77,518
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	35,410
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	19,067
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,751
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,751
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	45,778
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	24,659



TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,580
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,580
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,378
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	1,968
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	660
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	357
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	185
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	185
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	941
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the	508



	12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	263
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	263
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	100
HRH_PRE	By Graduates: Nurses	65
HRH_PRE	By Graduates: Laboratory professionals	35
HRH_PRE	Sum of Graduates disaggreagtes	100

Implementing Mechanism Details

Mechanism ID: 13776	Mechanism Name: CCS
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Center for Collaboration in Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 16,873,526	
Applied Pipeline Amount: 1,400,000	
Total All Funding Sources and Applied Pipeline Amount: 18,273,526	
Funding Source	Funding Amount
GHP-State	16,873,526



Cross-Cutting Budget Attribution(s)

Human Resources for Health	759,838
Gender: GBV	871,677
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation

Budget Code Information

Mechanism ID: 13776			
Mechanism Name: CCS			
Prime Partner Name: Center for Collaboration in Health			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	2,070,230	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	327,506	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	185,836	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	20,000	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	664,506	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	1,039,477	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	11,681,154	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	884,817	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	73,004
PMTCT_ART_DSD	New on ART	6,470
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	4,318
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	19,299
PMTCT_ART_TA	New on ART	990
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	655
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	73,004
PMTCT_STAT_DSD	Number of new ANC and L&D clients	73,741
PMTCT_STAT_DSD	By: Known positives at entry	4,362
PMTCT_STAT_DSD	By: Number of new positives identified	6,536
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	10,898



PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	19,299
PMTCT_STAT_TA	Number of new ANC and L&D clients	19,494
PMTCT_STAT_TA	By: Known positives at entry	664
PMTCT_STAT_TA	By: Number of new positives identified	997
PMTCT_STAT_TA	Sum of Positives Status disaggregates	1,661
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	162,077
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	16,739
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	23,559
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	18,577
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	103,221
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	35,316
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	126,780
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	162,096
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	1,165
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	6,146
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	1,246
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	13,132
HTC_TST_DSD	Service Delivery Point (Community): Index testing	5,502
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	25,919
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	1,046
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	365



HTC_TST_DSD	Service Delivery Point (Facility): VCT	28,537
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	67,586
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	277
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	32,845
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	121,146
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	9,177
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	21,599
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	11,602
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	78,768
HTC_TST_TA	Sum of Aggregated Age/Sex <15	20,779
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	100,367
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	121,146
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Male	374
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	3,375
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Female	461
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	6,547
HTC_TST_TA	Service Delivery Point (Facility): Outpatient	72,709
HTC_TST_TA	Service Delivery Point (Facility): Pediatric	1,436
HTC_TST_TA	Service Delivery Point (Facility): Other PITC	273
HTC_TST_TA	Service Delivery Point (Facility): VCT	27,248
HTC_TST_TA	Service Delivery Point (Facility): PMTCT	18,623
HTC_TST_TA	Service Delivery Point (Facility): TB Clinics	857
TB_STAT_DSD	Number of registered new and relapsed TB cases with	11,954

	documented HIV status, during the reporting period.	
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	11,954
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	4,184
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	7,772
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	2,242
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	2,242
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	785
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,457
GEND_GBV_DSD	Number of people receiving post-GBV care	4,299
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	3,235
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	1,087
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	808
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	7,616
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	7,616
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during	2,663



	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	4,953
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	4,953
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,173
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	1,173
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	412
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	762
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	193,877
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	6,327
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	63,439
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	6,327
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	117,810
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	15,511
TB_SCREENDX_TA	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	24,832
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Male	901
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Male	8,066
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Female	901
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Female	14,978



TB_SCREENDX_TA	Screen Results: Screened Positive for TB	1,988
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	7,075
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	3,181
PMTCT_EID_DSD	Sum of Infant Age disaggregates	10,256
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	348
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	252
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	916
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	415
PMTCT_EID_TA	Sum of Infant Age disaggregates	1,331
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	46
PMTCT_EID_TA	Number of infants with a positive virological test result within 12 months of birth	33
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	160,544
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	5,542
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	52,319
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	5,542
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	97,168
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	11,084
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	149,487
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	160,571
TX_CURR_DSD	Age/Sex: <1	355
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	22,406
TX_CURR_TA	Aggregated Age/Sex: <15 Male	1,069
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	7,099



TX_CURR_TA	Aggregated Age/Sex: <15 Female	1,069
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	13,181
TX_CURR_TA	Sum of Aggregated Age/Sex <15	2,138
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	20,280
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	22,418
TX_CURR_TA	Age/Sex: <1	70
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	39,694
TX_NEW_DSD	By Age/Sex: <1	355
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	23,137
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	12,458
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	2,061
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	2,061
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	39,717
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	6,538
TX_NEW_TA	Aggregated Grouping by Age: <1	70
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	3,793
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	2,042
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	355
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	355
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	6,545
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	25,030
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	33,374
TX_PVLS_DSD	Numerator: Indication: Routine	6,996
TX_PVLS_DSD	Numerator: Indication: Targeted	18,034
TX_PVLS_DSD	Denominator: Indication: Routine	9,327
TX_PVLS_DSD	Denominator: Indication: Targeted	24,047



TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	13,401
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	7,216
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	2,224
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	2,224
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	2,960
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	9,618
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	2,960
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	17,867
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	3,998
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	5,331
TX_PVLS_TA	Numerator: Indication: Routine	1,373
TX_PVLS_TA	Numerator: Indication: Targeted	2,625
TX_PVLS_TA	Denominator: Indication: Routine	1,829
TX_PVLS_TA	Denominator: Indication: Targeted	3,502
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Male	2,041
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Male	1,100
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Female	435
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Female	435
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Male	579
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Male	1,466
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Female	579
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Female	2,720
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	37,014
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	46,744



TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	22,070
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	11,884
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,541
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,541
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	27,878
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	15,013
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,941
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,941
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	4,696
TX_RET_TA	Total number of adults and children who initiated ART	6,707



	in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,774
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,495
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	220
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	220
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,961
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,134
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	309
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	309



HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	35
HRH_PRE	By Graduates: Other	35
HRH_PRE	Sum of Graduates disaggreagtes	35

Implementing Mechanism Details

Mechanism ID: 13784	Mechanism Name: INS
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Instituto Nacional de Saúde	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 4,394,308	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 4,394,308	
Funding Source	Funding Amount
GHP-State	4,394,308

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	13784		
Mechanism Name:	INS		
Prime Partner Name:	Instituto Nacional de Saúde		
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HVTB	1,106,720	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	405,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	800,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	1,320,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	430,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	317,588	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	15,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	127
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	114
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	115
LAB_PT_DSD	CD4: Number of laboratories that perform this testing	191



LAB_PT_DSD	CD4: Number of laboratories that participate in this PT program	179
LAB_PT_DSD	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	170
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that perform this testing	5
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that participate in this PT program	5
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	5
LAB_PT_DSD	HIV viral load: Number of laboratories that perform this testing	8
LAB_PT_DSD	HIV viral load: Number of laboratories that participate in this PT program	8
LAB_PT_DSD	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	8
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	344
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	157
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	133
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	59
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	59
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	56
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	3



LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	3
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	3

Implementing Mechanism Details

Mechanism ID: 14597		Mechanism Name: DevResults	
Funding Agency: USAID		Procurement Type: Contract	
Prime Partner Name: DevResults			
Agreement Start Date: Redacted		Agreement End Date: Redacted	
TBD: No		New Mechanism: No	
G2G: No		Managing Agency:	

Total All Funding Sources: 76,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 76,000	
Funding Source	Funding Amount
GHP-State	76,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 14597			
Mechanism Name: DevResults			
Prime Partner Name: DevResults			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	76,000	0



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14598	Mechanism Name: Health Policy Project
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Futures Group	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	14598		
Mechanism Name:	Health Policy Project		
Prime Partner Name:	Futures Group		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14639	Mechanism Name: Learning Capacity Development Task Order 1
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: EUROSIS - Consultoria e Formacao em Gestao, Lda	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:
Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	14639		
Mechanism Name:	Learning Capacity Development Task Order 1		
Prime Partner Name:	EUROSIS - Consultoria e Formacao em Gestao, Lda		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and	OHSS	0	0



Systems			
---------	--	--	--

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14644	Mechanism Name: Design and Build of Nampula Regional Pharmaceutical Warehouse
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Resolve Solution Partners (PTY), Ltd	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 14644			
Mechanism Name:	Design and Build of Nampula Regional Pharmaceutical Warehouse		
Prime Partner Name:	Resolve Solution Partners (PTY), Ltd		
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Governance and Systems	OHSS	0	0
------------------------	------	---	---

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14647	Mechanism Name: Construction of Rural Health Centers - 5 in Zambezia
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: ASNA Construções & Engenharia	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	14647		
Mechanism Name:	Construction of Rural Health Centers - 5 in Zambezia		
Prime Partner Name:	ASNA Construções & Engenharia		
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Governance and Systems	OHSS	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14650	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 14652	Mechanism Name: Health Management Twinning
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Columbia University Mailman School of Public Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 14652			
Mechanism Name: Health Management Twinning			
Prime Partner Name: Columbia University Mailman School of Public Health			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14670	Mechanism Name: Strengthening Health and Social Service System
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Foundation for Community Development, Mozambique	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 120,427	
Total All Funding Sources and Applied Pipeline Amount: 120,427	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 14670			
Mechanism Name: Strengthening Health and Social Service System			
Prime Partner Name: Foundation for Community Development, Mozambique			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14732	Mechanism Name: Accelerating Strategies for Practical Innovation & Research in Economic Strengthening (ASPIRES)
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID:	14732		
Mechanism Name:	Accelerating Strategies for Practical Innovation & Research in		
Prime Partner Name:	Economic Strengthening (ASPIRES)		
	FHI 360		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14739	Mechanism Name: Strengthen Family and Community Support to Orphan and Vulnerable Children (FORCA Project)
Funding Agency: USAID	Procurement Type: Grant
Prime Partner Name: World Education	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 1,554,206	
Applied Pipeline Amount: 1,849,775	
Total All Funding Sources and Applied Pipeline Amount: 3,403,981	
Funding Source	Funding Amount
GHP-State	1,554,206

Cross-Cutting Budget Attribution(s)

Economic Strengthening	300,000
Education	300,000



Gender: GBV	400,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Gender: Gender Equality	400,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Focus Area:	Equity in HIV prevention, care, treatment and support
Water	100,000

Budget Code Information

Mechanism ID:	14739		
Mechanism Name:	Strengthen Family and Community Support to Orphan and Vulnerable Children (FORCA Project)		
Prime Partner Name:	World Education		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	1,554,206	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	12,238
PP_PREV_DSD	Aggregated Age/sex: <15 Male	8,567
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	3,671
PP_PREV_DSD	Aggregated Age/sex: <15 Female	3,671



PP_PREV_DSD	Aggregated Age/sex: 15+ Female	2,448
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	107,778
OVC_SERV_DSD	Age/Sex: 18+ Male	2,155
OVC_SERV_DSD	Age/Sex: 18+ Female	4,312
OVC_SERV_DSD	Sum of Age/Sex disaggregates	6,467
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female <1	337
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	2,252
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	901
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	337
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 25+	225
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male <1	337
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	2,138
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	788
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24	225
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 25+	113
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female <1	152
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	1,010
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	404
OVC_SERV_DSD	Required only for DREAMS countries - By service, age	152



	and sex: Parenting/Caregiver Programs Female 18-24	
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+	101
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male <1	152
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14	958
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17	354
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24	101
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 25+	51
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female <1	559
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	3,728
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	1,491
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	559
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 25+	372
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male <1	559
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14	3,541
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17	1,304
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 18-24	372
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 25+	187
OVC_SERV_DSD	Required only for DREAMS countries - By service, age	58



	and sex: Economic Strengthening Female <1	
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14	389
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	154
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	58
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+	38
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male <1	58
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 10-14	369
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17	135
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24	38
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 25+	20
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female <1	58
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	389
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	154
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	58
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 25+	38
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male <1	58
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 10-14	369
OVC_SERV_DSD	Required only for DREAMS countries - By service, age	135



	and sex: Other Services Male 15-17	
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 18-24	38
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 25+	20
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support 1-9 Male	1,801
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 1-9	807
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Programs Male 1-9	2,981
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 1-9	310
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 1-9	310
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	49,577
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	51,733
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 1-9	1,801
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 1-9	807
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Programs Female 1-9	2,981
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 1-9	310
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 1-9	310

Implementing Mechanism Details

Mechanism ID: 14748	Mechanism Name: UNICEF MCH Umbrella Grant
Funding Agency: USAID	Procurement Type: Grant
Prime Partner Name: United Nations Children's Fund	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No

Approved



G2G: No	Managing Agency:
Total All Funding Sources: 300,000	
Applied Pipeline Amount: 500,000	
Total All Funding Sources and Applied Pipeline Amount: 800,000	
Funding Source	Funding Amount
GHP-State	300,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 14748			
Mechanism Name: UNICEF MCH Umbrella Grant			
Prime Partner Name: United Nations Children's Fund			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	300,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14789	Mechanism Name: EGPAF
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:



Total All Funding Sources: 21,895,240	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 21,895,240	
Funding Source	Funding Amount
GHP-State	21,895,240

Cross-Cutting Budget Attribution(s)

Human Resources for Health	490,970
Gender: GBV	916,342
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation

Budget Code Information

Mechanism ID: 14789			
Mechanism Name: EGPAF			
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	2,663,104	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	351,027	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	405,890	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	30,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	1,710,540	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	1,834,092	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	13,233,994	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	1,566,593	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	56,712
PMTCT_ART_DSD	New on ART	6,222
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	4,140
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	3,336
PMTCT_ART_TA	New on ART	310



PMTCT_ART_TA	Already on ART at beginning of current pregnancy	207
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	56,712
PMTCT_STAT_DSD	Number of new ANC and L&D clients	57,283
PMTCT_STAT_DSD	By: Known positives at entry	4,187
PMTCT_STAT_DSD	By: Number of new positives identified	6,282
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	10,469
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: <15	5
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 15-19	415
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 20-24	919
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 15-19	186
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 20-24	557
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15	668
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15-19	5,775
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 20-24	7,832
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 25-49	10,484
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 50+	21
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 25-49	1,101
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 50+	18
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 25-49	1,425



PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 50+	26
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): <15	660
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 15-19	5,717
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 20-24	7,754
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 25-49	10,379
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 50+	19
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	3,336
PMTCT_STAT_TA	Number of new ANC and L&D clients	3,369
PMTCT_STAT_TA	By: Known positives at entry	209
PMTCT_STAT_TA	By: Number of new positives identified	313
PMTCT_STAT_TA	Sum of Positives Status disaggregates	522
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	11,811
PP_PREV_DSD	Aggregated Age/sex: <15 Male	8,267
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	3,544
PP_PREV_DSD	Aggregated Age/sex: <15 Female	3,544
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	2,362
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	445,571
HTC_TST_DSD	Age/sex: 10-14 Male	8,513
HTC_TST_DSD	Age/sex: 15-19 Male	6,078
HTC_TST_DSD	Age/sex: 20-24 Male	5,958
HTC_TST_DSD	Age/sex: 25-49 Male	10,695
HTC_TST_DSD	Age/sex: 50+ Male	2,251
HTC_TST_DSD	Age/sex: 10-14 Female	4,703
HTC_TST_DSD	Age/sex: 15-19 Female	15,413
HTC_TST_DSD	Age/sex: 20-24 Female	22,765
HTC_TST_DSD	Age/sex: 25-49 Female	37,151



HTC_TST_DSD	Age/sex: 50+ Female	3,872
HTC_TST_DSD	Sum of Age/Sex disaggregates	117,399
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	227
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	423
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	1,050
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	4,634
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	987
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	350
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	1,269
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	2,831
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	6,774
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	995
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	55,186
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	77,263
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	60,474
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	252,750
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	115,660
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	330,013
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	445,673
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	3,714
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	23,571
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	4,303
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	39,353
HTC_TST_DSD	Test Result by Age: Positive: <1	308
HTC_TST_DSD	Test Result by Age: Positive: 1-9	1,343



HTC_TST_DSD	Age/sex: <1	3,660
HTC_TST_DSD	Age/sex: 1-9	14,779
HTC_TST_DSD	Service Delivery Point (Community): Index testing	33,680
HTC_TST_DSD	Service Delivery Point (Community): Other	2,818
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	235,636
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	15,474
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	7,036
HTC_TST_DSD	Service Delivery Point (Facility): VCT	62,980
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	52,039
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	2,227
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	33,681
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	8,980
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	642
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	899
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	884
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	6,555
HTC_TST_TA	Sum of Aggregated Age/Sex <15	1,526
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	7,454
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	8,980
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Male	29
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	189
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Female	37
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	627



HTC_TST_TA	Service Delivery Point (Facility): Outpatient	5,509
HTC_TST_TA	Service Delivery Point (Facility): Pediatric	225
HTC_TST_TA	Service Delivery Point (Facility): Other PITC	145
HTC_TST_TA	Service Delivery Point (Facility): PMTCT	3,068
HTC_TST_TA	Service Delivery Point (Facility): TB Clinics	33
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	8,397
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	8,397
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2,937
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	5,460
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	198
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	198
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	69
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	129
GEND_GBV_DSD	Number of people receiving post-GBV care	6,460
GEND_GBV_DSD	Age/Sex: <10 Male	27
GEND_GBV_DSD	Age/Sex: 10-14 Male	77
GEND_GBV_DSD	Age/Sex: 20-24 Male	77
GEND_GBV_DSD	Age/Sex: 25-49 Male	27
GEND_GBV_DSD	Age/Sex: <10 Female	130
GEND_GBV_DSD	Age/Sex: 10-14 Female	604
GEND_GBV_DSD	Age/Sex: 20-24 Female	604



GEND_GBV_DSD	Age/Sex: 25-49 Female	480
GEND_GBV_DSD	Sum of Age/Sex Disaggregates	838
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	4,864
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	1,634
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	1,207
GEND_GBV_DSD	Age/Sex: 15-19 Female	604
GEND_GBV_DSD	Age/Sex: 15-19 male	77
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	5,875
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	5,875
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	2,058
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	3,817
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	126
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	126
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	44
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The	82



	number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	141,752
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	5,069
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	46,083
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	5,069
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	85,580
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	11,339
TB_SCREENDX_TA	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	2,570
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Male	130
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Male	810
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Female	130
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Female	1,503
TB_SCREENDX_TA	Screen Results: Screened Positive for TB	206
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	6,661
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	2,996
PMTCT_EID_DSD	Sum of Infant Age disaggregates	9,657
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	337
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	238
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	289
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	130
PMTCT_EID_TA	Sum of Infant Age disaggregates	419



PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	14
PMTCT_EID_TA	Number of infants with a positive virological test result within 12 months of birth	10
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	123,460
TX_CURR_DSD	Age/Sex: 15-19 Male	1,335
TX_CURR_DSD	Age/Sex: 15-19 Female	1,974
TX_CURR_DSD	Sum of age/sex disaggregates	3,309
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	5,355
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	39,481
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	5,355
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	73,313
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	10,710
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	112,794
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	123,504
TX_CURR_DSD	Age/Sex: <1	215
TX_CURR_DSD	Age/Sex: <1-9	2,985
TX_CURR_DSD	Age/Sex: 10-14 Male	640
TX_CURR_DSD	Age/Sex: 10-14 Female	640
TX_CURR_DSD	Age/Sex: 20-24 Male	3,508
TX_CURR_DSD	Age/Sex: 25-49 Male	12,704
TX_CURR_DSD	Age/Sex: 50+ Male	2,917
TX_CURR_DSD	Age/Sex: 20-24 Female	4,522
TX_CURR_DSD	Age/Sex: 25-49 Female	10,303
TX_CURR_DSD	Age/Sex: 50+ Female	1,641
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	2,272
TX_CURR_TA	Aggregated Age/Sex: <15 Male	115
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	716
TX_CURR_TA	Aggregated Age/Sex: <15 Female	115
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	1,330



TX_CURR_TA	Sum of Aggregated Age/Sex <15	230
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	2,046
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	2,276
TX_CURR_TA	Age/Sex: <1	2
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	48,783
TX_NEW_DSD	By Age/Sex: <1	215
TX_NEW_DSD	By Age/Sex: 1-9	1,511
TX_NEW_DSD	By Age/Sex: 10-14 Male	158
TX_NEW_DSD	By Age/Sex: 15-19 Male	524
TX_NEW_DSD	By Age/Sex: 20-24 Male	1,379
TX_NEW_DSD	By Age/Sex: 25-49 Male	4,990
TX_NEW_DSD	By Age/Sex: 50+ Male	1,147
TX_NEW_DSD	By Age/Sex: 10-14 Female	319
TX_NEW_DSD	By Age/Sex: 15-19 Female	775
TX_NEW_DSD	By Age/Sex: 20-24 Female	1,777
TX_NEW_DSD	By Age/Sex: 25-49 Female	4,048
TX_NEW_DSD	By Age/Sex: 50+ Female	647
TX_NEW_DSD	Sum of Age/Sex disaggregates	15,764
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	28,713
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	15,467
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	2,328
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	2,328
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	48,836
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	523
TX_NEW_TA	Aggregated Grouping by Age: <1	2
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	303
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	163
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	29
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	29
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	524



TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	26,915
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	35,886
TX_PVLS_DSD	Numerator: Indication: Routine	5,284
TX_PVLS_DSD	Numerator: Indication: Targeted	21,631
TX_PVLS_DSD	Denominator: Indication: Routine	7,041
TX_PVLS_DSD	Denominator: Indication: Targeted	28,845
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	14,433
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	7,769
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	2,385
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	2,385
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	3,169
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	10,363
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	3,169
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	19,238
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	649
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	865
TX_PVLS_TA	Numerator: Indication: Routine	112
TX_PVLS_TA	Numerator: Indication: Targeted	537
TX_PVLS_TA	Denominator: Indication: Routine	148
TX_PVLS_TA	Denominator: Indication: Targeted	717
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Male	361
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Male	194
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Female	49



TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Female	49
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Male	64
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Male	258
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Female	64
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Female	480
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	38,408
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	49,553
TX_RET_DSD	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	292
TX_RET_DSD	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,111
TX_RET_DSD	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	144
TX_RET_DSD	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	399
TX_RET_DSD	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,049
TX_RET_DSD	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	3,801
TX_RET_DSD	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	874
TX_RET_DSD	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12	295



	months after initiating ART	
TX_RET_DSD	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,282
TX_RET_DSD	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,937
TX_RET_DSD	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6,690
TX_RET_DSD	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,067
TX_RET_DSD	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	321
TX_RET_DSD	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,221
TX_RET_DSD	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	162
TX_RET_DSD	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	437
TX_RET_DSD	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months	1,154



	prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4,179
TX_RET_DSD	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	960
TX_RET_DSD	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	325
TX_RET_DSD	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,409
TX_RET_DSD	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,231
TX_RET_DSD	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	7,363
TX_RET_DSD	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including	1,171



	those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	22,727
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	12,236
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,746
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,746
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	29,312
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	15,784
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,258
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,258
TX_RET_TA	Number of adults and children who are still alive and on	904



	treatment at 12 months after initiating ART	
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	1,292
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	455
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	245
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	103
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	103
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	649
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	349
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	149
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	149



	including those who have died, those who have stopped ART, and those lost to follow-up)	
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	131
HRH_PRE	By Graduates: Nurses	65
HRH_PRE	By Graduates: Laboratory professionals	30
HRH_PRE	By Graduates: Other	36
HRH_PRE	Sum of Graduates disaggreagtes	131

Implementing Mechanism Details

Mechanism ID: 14792	Mechanism Name: ISCISA
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: ISCISA- Superior Institution of Health Sciences	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	14792
----------------------	-------



Mechanism Name: ISCISA			
Prime Partner Name: ISCISA- Superior Institution of Health Sciences			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	65
HRH_PRE	By Graduates: Nurses	35
HRH_PRE	By Graduates: Other	30
HRH_PRE	Sum of Graduates disaggreagtes	65

Implementing Mechanism Details

Mechanism ID: 14806	Mechanism Name: P/E Quick Impact Program
Funding Agency: State/AF	Procurement Type: Grant
Prime Partner Name: U.S. Department of State	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 425,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 425,000	
Funding Source	Funding Amount
GHP-State	425,000

Cross-Cutting Budget Attribution(s)



(No data provided.)

Budget Code Information

Mechanism ID: 14806			
Mechanism Name: P/E Quick Impact Program			
Prime Partner Name: U.S. Department of State			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	36,845	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	323,155	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	15,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	50,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	700
PP_PREV_DSD	Aggregated Age/sex: <15 Male	144
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	210
PP_PREV_DSD	Aggregated Age/sex: <15 Female	206
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	140



OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	6,595
OVC_SERV_DSD	Age/Sex: 18+ Male	130
OVC_SERV_DSD	Age/Sex: 18+ Female	264
OVC_SERV_DSD	Sum of Age/Sex disaggregates	394
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	3,034
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	3,166

Implementing Mechanism Details

Mechanism ID: 14822	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 16052	Mechanism Name: UCSF-HQ
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of California at San Francisco	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 422,721	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 422,721	
Funding Source	Funding Amount
GHP-State	422,721

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 16052			
Mechanism Name: UCSF-HQ			
Prime Partner Name: University of California at San Francisco			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	22,721	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	400,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16671	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 16802	Mechanism Name: DPS Inhambane Province
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Provincial Directorate of Health, Inhambane	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 145,484	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 145,484	



Funding Source	Funding Amount
GHP-State	145,484

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 16802			
Mechanism Name: DPS Inhambane Province			
Prime Partner Name: Provincial Directorate of Health, Inhambane			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	57,742	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	30,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	57,742	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16879	Mechanism Name: World Food Program
Funding Agency: USAID	Procurement Type: Grant
Prime Partner Name: World Food Program	
Agreement Start Date: Redacted	Agreement End Date: Redacted

Approved



TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 2,000,000	
Applied Pipeline Amount: 1,000,000	
Total All Funding Sources and Applied Pipeline Amount: 3,000,000	
Funding Source	Funding Amount
GHP-State	2,000,000

Cross-Cutting Budget Attribution(s)

Food and Nutrition: Commodities	1,199,900
Food and Nutrition: Policy, Tools, and Service Delivery	790,020
Motor Vehicles: Leased	10,080

Budget Code Information

Mechanism ID:	16879		
Mechanism Name:	World Food Program		
Prime Partner Name:	World Food Program		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	2,000,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0

Implementing Mechanism Indicator Information

(No data provided.)



Implementing Mechanism Details

Mechanism ID: 16900	Mechanism Name: Mobile Solutions Technical Assistance and Research (mSTAR)
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	16900		
Mechanism Name:	Mobile Solutions Technical Assistance and Research (mSTAR)		
Prime Partner Name:	FHI 360		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

Implementing Mechanism Indicator Information

(No data provided.)



Implementing Mechanism Details

Mechanism ID: 16998	Mechanism Name: DPS Gaza Province
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Provincial Directorate of Health, Gaza	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 388,710	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 388,710	
Funding Source	Funding Amount
GHP-State	388,710

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 16998			
Mechanism Name: DPS Gaza Province			
Prime Partner Name: Provincial Directorate of Health, Gaza			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	144,355	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount

Approved



Treatment	HTXS	144,355	0
-----------	------	---------	---

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16999	Mechanism Name: DPS Nampula Province
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Provincial Directorate of Health, Nampula	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 273,226	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 273,226	
Funding Source	Funding Amount
GHP-State	273,226

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	16999		
Mechanism Name:	DPS Nampula Province		
Prime Partner Name:	Provincial Directorate of Health, Nampula		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	86,613	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	86,613	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17044	Mechanism Name: Ministry of Health (MISAU)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ministry of Health, Mozambique	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 4,251,674	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 4,251,674	
Funding Source	Funding Amount
GHP-State	4,251,674

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information



Mechanism ID: 17044			
Mechanism Name: Ministry of Health (MISAU)			
Prime Partner Name: Ministry of Health, Mozambique			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	481,183	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	481,183	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	240,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	620,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	202,508	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	392,500	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	529,300	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	805,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17104	Mechanism Name: Demographic and Health Survey's Program- Phase 7
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: ICF Macro	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 350,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 350,000	
Funding Source	Funding Amount
GHP-State	350,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17104
Mechanism Name:	Demographic and Health Survey's Program- Phase 7
Prime Partner Name:	ICF Macro



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	350,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17169	Mechanism Name: Mozambique Strategic Information Program (M-SIP)
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: John Snow Inc (JSI)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 762,828	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 762,828	
Funding Source	Funding Amount
GHP-State	762,828

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 17169



Mechanism Name:	Mozambique Strategic Information Program (M-SIP)		
Prime Partner Name:	John Snow Inc (JSI)		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	150,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	312,500	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	300,328	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17171	Mechanism Name: N"weti - Strengthening Civil Society Engagement to Improve Sexual and Reproductive Health and Service Delivery for Youth		
Funding Agency: USAID	Procurement Type: Contract		
Prime Partner Name: N'WETI - Comunicação para Saúde			
Agreement Start Date: Redacted	Agreement End Date: Redacted		
TBD: No	New Mechanism: No		
G2G: No	Managing Agency:		

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0



Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17171		
Mechanism Name:	N"weti - Strengthening Civil Society Engagement to Improve Sexual and Reproductive Health and Service Delivery for Youth		
Prime Partner Name:	N'WETI - Comunicação para Saúde		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	8,649
PP_PREV_DSD	Aggregated Age/sex: <15 Male	6,055
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	2,595
PP_PREV_DSD	Aggregated Age/sex: <15 Female	2,595
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	1,730
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	8,649
HTC_TST_DSD	Age/sex: 15-19 Female	1,683
HTC_TST_DSD	Age/sex: 20-24 Female	2,486
HTC_TST_DSD	Age/sex: 25-49 Female	4,057
HTC_TST_DSD	Age/sex: 50+ Female	423
HTC_TST_DSD	Sum of Age/Sex disaggregates	8,649



HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	70
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	157
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	376
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	56
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	8,649
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	8,649
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	8,649
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	659
HTC_TST_DSD	Service Delivery Point (Community): Other	8,649

Implementing Mechanism Details

Mechanism ID: 17259	Mechanism Name: Fortalecimento do Sistema de Monitoria e Avaliacao do MMAS
Funding Agency: USAID	Procurement Type: Grant
Prime Partner Name: JEMBI	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 350,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 350,000	
Funding Source	Funding Amount
GHP-State	350,000

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID:	17259		
Mechanism Name:	Fortalecimento do Sistema de Monitoria e Avaliacao do MMAS		
Prime Partner Name:	JEMBI		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	350,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17260	Mechanism Name: Esperança de Vida
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: REENCONTRO - Associação Moçambicana Para Apoio e Desenvolvimento da Criança Orfã	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID:	17260		
Mechanism Name:	Esperança de Vida		
Prime Partner Name:	REENCONTRO - Associação Moçambicana Para Apoio e Desenvolvimento da Criança Orfã		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17261	Mechanism Name: Improving Integrated HIV Homecare Services
Funding Agency: USAID	Procurement Type: Grant
Prime Partner Name: Associacao Nacional dos Enfermeiros de Mocambique (ANEMO)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 17261			
Mechanism Name: Improving Integrated HIV Homecare Services			
Prime Partner Name: Associacao Nacional dos Enfermeiros de Mocambique (ANEMO)			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17567		Mechanism Name: NASTAD	
Funding Agency: HHS/CDC		Procurement Type: Cooperative Agreement	
Prime Partner Name: National Alliance of State and Territorial AIDS Directors			
Agreement Start Date: Redacted		Agreement End Date: Redacted	
TBD: No		New Mechanism: No	
G2G: No		Managing Agency:	

Total All Funding Sources: 1,004,105	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,004,105	
Funding Source	Funding Amount
GHP-State	1,004,105

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 17567			
Mechanism Name: NASTAD			
Prime Partner Name: National Alliance of State and Territorial AIDS Directors			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	1,004,105	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17571	Mechanism Name: Nursing Capacity Building Program
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement
Prime Partner Name: Columbia University Mailman School of Public Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 17571			
Mechanism Name: Nursing Capacity Building Program			
Prime Partner Name: Columbia University Mailman School of Public Health			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17652	Mechanism Name: Food Security Innovation Lab: Collaborative Research on Assets and Market Access
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: University of California	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 250,000	
Total All Funding Sources and Applied Pipeline Amount: 250,000	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID:	17652		
Mechanism Name:	Food Security Innovation Lab: Collaborative Research on Assets and		
Prime Partner Name:	Market Access University of California		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17723	Mechanism Name: FADM Prevention and Circumcision Program
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: JHPIEGO	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 2,046,616	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 2,046,616	
Funding Source	Funding Amount
GHP-State	2,046,616

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 17723			
Mechanism Name: FADM Prevention and Circumcision Program			
Prime Partner Name: JHPIEGO			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	2,046,616	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	29,406
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	19,390
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	2,364
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	17,025
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	2,364
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	17,025
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	19,389
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	24
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	170
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	19,390



Implementing Mechanism Details

Mechanism ID: 18099	Mechanism Name: Linkages Across the Continuum of HIV Services for Key Populations affected by HIV (LINKAGES) Project
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	18099		
Mechanism Name:	Linkages Across the Continuum of HIV Services for Key Populations affected by HIV (LINKAGES) Project		
Prime Partner Name:	FHI 360		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

Implementing Mechanism Indicator Information

Approved



(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18100	Mechanism Name: Primary School Retention and Transition to Secondary School for Vulnerable Girls in Zambezia
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Ajuda de Desenvolvimento de Povo para Povo	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	18100		
Mechanism Name:	Primary School Retention and Transition to Secondary School for Vulnerable Girls in Zambezia		
Prime Partner Name:	Ajuda de Desenvolvimento de Povo para Povo		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18101	Mechanism Name: Maternal and Child Survival Program (MCSP)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: JHPIEGO	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 500,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 500,000	
Funding Source	Funding Amount
GHP-State	500,000

Cross-Cutting Budget Attribution(s)

Gender: Gender Equality	100,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Implementation
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Focus Area:	Equity in HIV prevention, care, treatment and support



Budget Code Information

Mechanism ID: 18101			
Mechanism Name: Maternal and Child Survival Program (MCSP)			
Prime Partner Name: JHPIEGO			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	500,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18102	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18103	Mechanism Name: Service Delivery and Support for Orphans and Vulnerable Children
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 3,091,965	
Applied Pipeline Amount: 10,300,357	
Total All Funding Sources and Applied Pipeline Amount: 13,392,322	
Funding Source	Funding Amount
GHP-State	3,091,965



Cross-Cutting Budget Attribution(s)

Economic Strengthening	500,000
Gender: Gender Equality	500,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Implementation
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Focus Area:	Equity in HIV prevention, care, treatment and support
Education	500,000
Gender: GBV	500,000
Focus Area:	GBV Prevention
Human Resources for Health	500,000
Water	200,000

Budget Code Information

Mechanism ID: 18103			
Mechanism Name: Service Delivery and Support for Orphans and Vulnerable Children			
Prime Partner Name: FHI 360			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	3,091,965	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by	304,667



	HIV/AIDS	
OVC_SERV_DSD	Age/Sex: 18+ Male	6,097
OVC_SERV_DSD	Age/Sex: 18+ Female	12,186
OVC_SERV_DSD	Sum of Age/Sex disaggregates	18,283
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	140,147
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	146,239

Implementing Mechanism Details

Mechanism ID: 18104	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18108	Mechanism Name: FADM HIV Treatment Scale-Up Program
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: JHPIEGO	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 2,094,727	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 2,094,727	
Funding Source	Funding Amount
GHP-State	2,094,727

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID:	18108		
Mechanism Name:	FADM HIV Treatment Scale-Up Program		
Prime Partner Name:	JHPIEGO		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	58,363	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	20,596	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	253,398	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	5,426	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,642,665	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	114,279	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	2,767
PMTCT_ART_DSD	New on ART	111
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received	2,767



	their results)	
PMTCT_STAT_DSD	Number of new ANC and L&D clients	2,767
PMTCT_STAT_DSD	By: Number of new positives identified	138
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	138
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	37,636
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	750
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	21,263
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,124
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	14,499
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	1,874
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	35,762
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	37,636
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	53
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	2,534
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	80
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	1,084
HTC_TST_DSD	Service Delivery Point (Community): Other	12,344
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	19,906
HTC_TST_DSD	Service Delivery Point (Facility): VCT	1,646
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	2,767
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	973
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	669



TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	669
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	13
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	254
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	20
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	382
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	335
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	335
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	7
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	127
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	10
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during	191



	TB treatment during the reporting period)	
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	3,515
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	70
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	1,957
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	106
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	1,382
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	422
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	703
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	562
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	141
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	124
PMTCT_EID_DSD	Sum of Infant Age disaggregates	124
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	6
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	11,718
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	235
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	6,524
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	352
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	4,607
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	587
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	11,131
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	11,718
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	3,474
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	906
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	2,503



TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	39
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	26
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	3,474
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	2,779
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	3,474
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	725
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,002
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	31
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	21
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	906
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,503
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	39



	stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	26

Implementing Mechanism Details

Mechanism ID: 18110	Mechanism Name: ARC - Nursing Council
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: African Health Profession Regulatory Collaborative for Nurses and Midwives	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	18110		
Mechanism Name:	ARC - Nursing Council		
Prime Partner Name:	African Health Profession Regulatory Collaborative for Nurses and Midwives		
Strategic Area	Budget Code	Planned Amount	On Hold Amount

Approved



Governance and Systems	OHSS	0	0
------------------------	------	---	---

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18122	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18123	Mechanism Name: Parceria Civica para Boa Governacao
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Counterpart International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 150,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 150,000	
Funding Source	Funding Amount
GHP-State	150,000

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 18123			
Mechanism Name: Parceria Civica para Boa Governacao			
Prime Partner Name: Counterpart International			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	150,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18275	Mechanism Name: Strengthening High Impact Interventions for an AIDS-Free Generation (AIDSFree) Project
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: John Snow Inc (JSI)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

Total All Funding Sources: 5,914,191	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 5,914,191	
Funding Source	Funding Amount
GHP-State	5,914,191

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID:	18275		
Mechanism Name:	Strengthening High Impact Interventions for an AIDS-Free Generation		
Prime Partner Name:	(AIDSFree) Project		
	John Snow Inc (JSI)		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	5,914,191	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	95,296
VMMC_CIRC_DSD	By Age: 10-14	23,824
VMMC_CIRC_DSD	By Age: 15-19	28,589
VMMC_CIRC_DSD	By Age: 20-24	23,824
VMMC_CIRC_DSD	By Age: 25-29	14,295
VMMC_CIRC_DSD	By Age: 30-49	4,764
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	76,237
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	95,296
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	95,296
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	95,296
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	23,826
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	71,474
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	23,826



HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	71,474
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	95,300
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	37
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	1,201
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	95,296

Implementing Mechanism Details

Mechanism ID: 18280	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18282	Mechanism Name: Global Health Supply Chain Program
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Global Health Supply Chain Program	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

Total All Funding Sources: 57,200,196	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 57,200,196	
Funding Source	Funding Amount
GHP-State	57,200,196

Cross-Cutting Budget Attribution(s)

Condom procurement	650,000
--------------------	---------



Budget Code Information

Mechanism ID: 18282			
Mechanism Name: Global Health Supply Chain Program			
Prime Partner Name: Global Health Supply Chain Program			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	4,215,440	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	1,600,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	825,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	8,650,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXD	31,500,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	7,885,670	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	2,424,086	0

Implementing Mechanism Indicator Information



Indicator Number	Label	2017
INVS_COMD	Number of HIV Test Kits purchased	9,650,000
INVS_COMD	Number of HIV CD4 Reagents purchased	563,602
INVS_COMD	Number of Condoms purchased	0
INVS_COMD	Number of HIV Viral Load Reagents purchased	412,500
INVS_COMD	HIV Test Kits: Dollars planned (COP)/ spent (Actual)	9,742,728

Implementing Mechanism Details

Mechanism ID: 18311	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18312	Mechanism Name: Integrating Early Child Development (ECD - GDA)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Program for Appropriate Technology in Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID:	18312		
Mechanism Name:	Integrating Early Child Development (ECD - GDA)		
Prime Partner Name:	Program for Appropriate Technology in Health		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18319	Mechanism Name: HIV Community-Based Services (Nampula)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Associação Para o Desenvolvimento Sócio-Económico	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

Total All Funding Sources: 816,268	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 816,268	
Funding Source	Funding Amount
GHP-State	816,268

Cross-Cutting Budget Attribution(s)

Condom programming	20,000
Economic Strengthening	389,324



Gender: GBV	100,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Gender: Gender Equality	100,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Focus Area:	Equity in HIV prevention, care, treatment and support
Water	50,000

Budget Code Information

Mechanism ID:	18319		
Mechanism Name:	HIV Community-Based Services (Nampula)		
Prime Partner Name:	Associação Para o Desenvolvimento Sócio-Económico		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	665,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	151,268	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	12,852
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION	4,086



	ONLY: <15 Male	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	3,141
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	4,086
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	1,576
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	8,172
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	4,717
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	12,889
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	136
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	453
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	136
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	226
HTC_TST_DSD	Service Delivery Point (Community): Index testing	12,852

Implementing Mechanism Details

Mechanism ID: 18336	Mechanism Name: 4 Children (Coordinating Comprehensive Care for Children)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Catholic Relief Services	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

Total All Funding Sources: 700,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 700,000	
Funding Source	Funding Amount
GHP-State	700,000



Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	18336		
Mechanism Name:	4 Children (Coordinating Comprehensive Care for Children)		
Prime Partner Name:	Catholic Relief Services		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	700,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	120
HRH_PRE	By Graduates: Social service workers	120
HRH_PRE	Sum of Graduates disaggreagtes	120

Implementing Mechanism Details

Mechanism ID: 18366	Mechanism Name: Health Finance and Governance Project (HFG)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Abt Associates	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes

Approved



G2G: No	Managing Agency:
Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 18366			
Mechanism Name: Health Finance and Governance Project (HFG)			
Prime Partner Name: Abt Associates			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18367	Mechanism Name: EQUIP
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Right To Care, South Africa	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes

Approved



G2G: No	Managing Agency:
Total All Funding Sources: 1,204,662	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,204,662	
Funding Source	Funding Amount
GHP-State	1,204,662

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 18367			
Mechanism Name: EQUIP			
Prime Partner Name: Right To Care, South Africa			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,204,662	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18368	Mechanism Name: Health Communication Capacity Collaborative (HC3)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Johns Hopkins University Bloomberg School of Public Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes



G2G: No	Managing Agency:
Total All Funding Sources: 1,035,394	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,035,394	
Funding Source	Funding Amount
GHP-State	1,035,394

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 18368			
Mechanism Name: Health Communication Capacity Collaborative (HC3)			
Prime Partner Name: Johns Hopkins University Bloomberg School of Public Health			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	360,394	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	250,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	150,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	275,000	0

Implementing Mechanism Indicator Information

Approved



(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18372	Mechanism Name: CMAM Agreement
Funding Agency: USAID	Procurement Type: Grant
Prime Partner Name: Central de Medicamentos e Artigos Medicos (CMAM)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: Yes	Managing Agency: USAID

Total All Funding Sources: 480,526	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 480,526	
Funding Source	Funding Amount
GHP-State	480,526

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	18372		
Mechanism Name:	CMAM Agreement		
Prime Partner Name:	Central de Medicamentos e Artigos Medicos (CMAM)		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	480,526	0

Implementing Mechanism Indicator Information

(No data provided.)



Implementing Mechanism Details

Mechanism ID: 18373	Mechanism Name: Health Policy Plus (HP+)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Palladium Group	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

Total All Funding Sources: 150,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 150,000	
Funding Source	Funding Amount
GHP-State	150,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	18373		
Mechanism Name:	Health Policy Plus (HP+)		
Prime Partner Name:	Palladium Group		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	150,000	0

Implementing Mechanism Indicator Information

(No data provided.)



Implementing Mechanism Details

Mechanism ID: 18429	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18454	Mechanism Name: ASLM
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: African Society for Laboratory Medicine	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

Total All Funding Sources: 240,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 240,000	
Funding Source	Funding Amount
GHP-State	240,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 18454			
Mechanism Name: ASLM			
Prime Partner Name: African Society for Laboratory Medicine			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and	HLAB	240,000	0

Approved



Systems			
---------	--	--	--

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18455	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18456	Mechanism Name: YouthPower Implementation - Task Order 1
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 1,128,530	
Total All Funding Sources and Applied Pipeline Amount: 1,128,530	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information



Mechanism ID: 18456			
Mechanism Name: YouthPower Implementation - Task Order 1			
Prime Partner Name: FHI 360			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18466	Mechanism Name: Project SOAR (Supporting Operational AIDS Research)
Funding Agency: USAID	Procurement Type: Umbrella Agreement
Prime Partner Name: Population Council	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information



Mechanism ID: 18466			
Mechanism Name: Project SOAR (Supporting Operational AIDS Research)			
Prime Partner Name: Population Council			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18478	TBD: Yes
REDACTED	

Agency Information - Costs of Doing Business U.S. Agency for International Development

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
Computers/IT Services		437,084		0	437,084	437,084
ICASS		1,415,636		0	1,415,636	1,415,636
Indirect Costs		566,748		0	566,748	566,748
Institutional Contractors		108,690		0	108,690	108,690
Management Meetings/Profes		87,703		0	87,703	87,703



sional Development						
Non-ICASS Administrative Costs		479,255		0	479,255	479,255
Staff Program Travel		805,592		0	805,592	805,592
USG Renovation		69,890		0	69,890	69,890
USG Staff Salaries and Benefits - Internationally Recruited		1,701,509		0	1,701,509	1,701,509
USG Staff Salaries and Benefits - Locally Recruited		1,327,893		0	1,327,893	1,327,893
Total	0	7,000,000	0	0	7,000,000	7,000,000

U.S. Department of Defense

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
ICASS		52,278		0	52,278	52,278
Management Meetings/Profes		15,467		0	15,467	15,467



sional Development						
Non-ICASS Administrative Costs		17,252		0	17,252	17,252
Non-ICASS Motor Vehicles		50,000		0	50,000	50,000
Staff Program Travel		40,981		0	40,981	40,981
USG Staff Salaries and Benefits - Locally Recruited		169,930		0	169,930	169,930
Total	0	345,908	0	0	345,908	345,908

U.S. Department of Health and Human Services/Centers for Disease Control and Prevention

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
Capital Security Cost Sharing		1,268,175		0	1,268,175	1,268,175
Computers/IT Services		674,505		0	674,505	674,505
ICASS		2,687,585		0	2,687,585	2,687,585
Non-ICASS Administrative	454,145	3,549,714		0	4,003,859	4,003,859



Costs						
Staff Program Travel		1,432,270		0	1,432,270	1,432,270
USG Staff Salaries and Benefits - Internationally Recruited	2,620,855	1,287,427		0	3,908,282	3,908,282
USG Staff Salaries and Benefits - Locally Recruited	0	3,767,974		0	3,767,974	3,767,974
Total	3,075,000	14,667,650	0	0	17,742,650	17,742,650

U.S. Department of State

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
Computers/IT Services		1,788		4,000	1,788	5,788
ICASS		215,728		0	215,728	215,728
Management Meetings/Professional Development		270,000		8,000	270,000	278,000
Non-ICASS Administrative		188,500		66,000	188,500	254,500



Costs						
Staff Program Travel		344,998		145,000	344,998	489,998
USG Staff Salaries and Benefits - Internationally Recruited		284,832		0	284,832	284,832
USG Staff Salaries and Benefits - Locally Recruited		371,961		100,780	371,961	472,741
Total	0	1,677,807	0	323,780	1,677,807	2,001,587

U.S. Peace Corps

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
ICASS		184,324		0	184,324	184,324
Peace Corps Volunteer Costs		2,379,676		0	2,379,676	2,379,676
Staff Program Travel		86,261		0	86,261	86,261
USG Staff Salaries and Benefits - Locally		336,197		0	336,197	336,197

Approved



Recruited						
Total	0	2,986,458	0	0	2,986,458	2,986,458